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 Natural products produced by bacteria have been an excellent source of bioactive 
small molecules. The diverse structures and bioactivates of natural products make them 
useful compounds in multiple fields, ranging from biochemistry, to medicine, to agriculture. 
Two interesting classes of enzymes that produce a diverse set of natural products are the 
assembly line like proteins nonribosomal peptide synthetases (NRPS) and polyketide 
synthases (PKS). The thiomarinol pathway contains both of these classes of enzymes, and I 
characterized the enzymes from this pathway responsible for linking two separate NRPS and 
PKS antibiotics into the hybrid antibiotic thiomarinol. The biosynthetic scheme utilized by 
the thiomarinol pathway represents a novel strategy to make NRPS/PKS hybrids in nature. I 
also developed a new method for studying NRPS systems using the molecular probe 
cysteamine to capture and detect intermediates produced during in vitro reactions. I then used 
this method to elucidate the biosynthesis of the NRPS pathway that produces the 
oxyvinylglycine L-2-amino-4-methoxy-trans-3-butenoic acid (AMB). Since cysteamine 
captures intermediates that are linked through a thioester bond utilized by both NRPS and 
PKS enzymes, future studies will be able to use the cysteamine in vitro reaction to 
characterize both classes of enzymes. Lastly, I identified two new oxyvinylglycines produced 
by the gvg gene cluster, which was already known to produce 4-formylaminooxyvinylglycine 
iv 
(FVG). Through metabolomic and biochemical studies, I provided new insights into the 
biosyntheses of these three oxyvinylglycine metabolites and provided a background for 
future studies to characterize the activity of new enzymatic reactions from the gvg pathway. 
Together, this work characterizes and provides insights into the activities of ten enzymes 
throughout three separate pathways, which will aid in the characterization of homologous 
pathways found throughout nature. A better understanding of these natural product pathways 
and enzymes will afford the ability to modulate the pathways to produce non-natural 
products with altered bioactivities.   
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CHAPTER 1:  CHARACTERIZING SECONDARY METABOLITE PATHWAYS 
LEADS TO THE IDENTIFICATION OF NOVEL NATURAL PRODUCTS AND 
ENZYMATIC REACTIONS 
Enzyme Introduction   
Within living cells, thousands of chemical reactions are occurring simultaneously, 
and enzymes catalyze virtually all of these reactions. Thus, understanding the role and 
function of enzymes is paramount to understanding biological systems and processes. The 
first studies that attempted to characterize enzymes began over 100 years ago, when it was 
discovered that biological catalysis can occur outside of cells.1 Since the first identification of 
these biological catalysts, countless studies have been performed to determine  how they 
function and what roles they play in biochemical processes. From these studies many 
fundamental enzyme features have been discovered, such as the existence of cofactors and 
inhibitors, allosteric regulation, and the basics of enzyme kinetics.2 One of the driving 
motivations behind these studies has been the desire to harvest the ability of enzymes to 
enhance reaction rates under relatively mild or physiologic conditions. 
 Compared to traditional organic catalysts, enzymes have many advantages. First, 
enzymes perform regiospecific and stereospecific reactions due to the chiral nature of their 
amino acid building blocks. Second, enzymes perform chemistry in relatively mild aqueous 
conditions compared to organic chemical syntheses, eliminating the need for organic solvents 
or the energy needed for heating or cooling of solutions. Third, enzymes perform chemistry 
with reactive intermediates in the presence of other functional groups.3 Together these traits 
provide enzymes with the potential to be efficient and green alternatives to organic chemical 
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syntheses. In fact, many enzymes have already been used as biocatalysts in the synthesis of 
pharmaceuticals.4–6 For example, a monooxygenase from Rhodococcus catalyzes the chiral 
hydroxylation of an indole precursor of Crixivan an HIV protease inhibitor. The 
monooxygenase installs two chiral hydroxyls that are required for activity in the final 
compound.4,5 Also, enzymes are used to make modifications to bioactive molecules to 
improve pharmacokinetic profiles.  For example, Ribavirin is an antiviral used in the 
treatment of hepatitis C, and the conversion of ribavirin into an improved prodrug is done by 
selectively modifying one of three hydroxyls of the parent compound. The prodrug has been 
produced and isolated in 82% yield on the kilogram scale using Candidia antarctica lipase B, 
eliminating the need for costly and time consuming selective protection and deprotections 
steps.6 While some classes of enzymes are characterized and can be used in these syntheses, 
there are still many classes that are uncharacterized and have the potential to expand the 
biocatalytic toolbox. One source of uncharacterized enzymes are microbial pathways that 
produce molecules that are not necessary for reproduction but provide the organism a 
selective advantage; known as secondary metabolites. 
 Enzymes involved in microbe secondary metabolism have been a focus of many 
studies in recent years. The metabolites from these pathways represent a wealth of bioactive 
compounds that contain functional groups that are rarely found in primary metabolism, 
including diazo groups (azaserine), enediynes (calicheamicin), and thiosulfinates 
(leinamycin) among others (Figure 1.1). While these bioactive metabolites were first 
identified decades ago, as far back as 1954 in the case of azaserine,7 the biosynthesis of many 
secondary metabolites have only recently been elucidated. The expansion of genome 
sequencing in the 1990’s caused a paradigm shift in the field and allowed for new 
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bioinformatic techniques to analyze the genes responsible for secondary metabolite 
production. Prior to this period, it was challenging for researchers to identify a single gene of 
interest and purify the corresponding protein for in vitro studies. Now, with the availability of 
many microbial genomic sequences, computational programs have been developed that are 
able to connect isolated compounds to putative biosynthetic gene clusters, and vice versa.8 In 
a few short years, the ability of investigators to characterize enzymes involved in microbial 
secondary metabolism took a giant step forward. 
 
Figure 1.1 – Structures of microbial secondary metabolites that have interesting functional 
groups, with the producing strain for each listed.7,9,10  
Genome guided strategies for characterizing secondary metabolite enzymes 
In bacteria, the genes responsible for a single metabolic pathway often cluster 
together. This was originally observed in primary metabolism in the 1970’s,11 and it holds 
true for secondary metabolites. Therefore, researchers can search the genome of any 
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sequenced microbial strain to identify possible secondary metabolite gene clusters in order to 
discover the full potential of secondary metabolites each strain can produce. It is estimated 
that many actinobacteria can produce 20 to 30 different secondary metabolites, 
approximately 10 times the number identified in culture extracts.12 Under the current 
paradigm, the general workflow to identify new secondary metabolites and characterize the 
enzymes in each pathway is shown in Figure 1.2.  
 
Figure 1.2- The workflow of characterizing enzymes of secondary metabolite natural product 
pathways.  
The first step involves the identification of potentially new biosynthetic gene clusters 
by leveraging multiple computational software programs to parse through the extensive 
amounts of genomic data available.  The two most commonly used computational search 
tools are Basic Local Alignment Search Tool (BLAST) and antibiotics & Secondary 
Metabolite Analysis Shell (antiSMASH).13,14 BLAST uses a gene or protein sequence of 
interest, also known as a “biosynthetic hook”, as a query to search any of the genomes 
available through NCBI. Combined with the collective information of the Conserved Domain 
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Database (CDD), putative enzymatic functions can be assigned to genes solely from the 
genetic or protein sequence.15,16 As a complementary program, antiSMASH is able to 
identify all gene clusters within a given genome that are predicted to produce a secondary 
metabolite and compare them against other characterized clusters.14 Using BLAST and 
antiSMASH together, researchers can predict a reasonable pathway for a given gene cluster if 
the product is known, without any additional experimental data. For some well-studied 
classes of secondary metabolites even the structure of the product can be predicted with some 
accuracy, however there are still limitations to these predictions. 
The most successful predicted functions are from nonribosomal peptide synthetase 
(NRPS) and polyketide synthase (KS) containing gene clusters. Both of these classes of 
proteins are large modular assembly-line-like enzymes. Substrates are covalently tethered to 
the protein and undergo reactions by modifying domains and separate enzymes, called 
tailoring enzymes.17,18 For PKS and NRPS pathways, even the substrates of the enzymes can 
be accurately predicted, which is a task that is difficult for other classes of enzymes. In 
nature, PKS enzymes use either malonyl-CoA or methylmalonyl-CoA as substrates which 
can be predicted by sequence similarities of certain domains.17 NRPS enzymes are more 
difficult to predict since the 20 proteinogenic amino acids as well as hundreds of non-
proteinogenic amino acids can be used as substrates. Although, the high structural similarity 
between NRPS domains allowed Stachelhaus et al. to identify 10 key residues that determine 
substrate specificity, known as the Stachelhaus code.19 The Stachelhaus code is now 
incorporated into multiple free online programs that will predict NRPS amino acids 
substrates from genomic data, such as antiSMASH, NaPDoS, and NRPSPredictor.14,20,21 This 
work was advanced further in 2016, when researchers were able to successfully connect 
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previously isolated PKS and NRPS products to uncharacterized gene clusters using only 
bioinformatics.8 While bioinformatic analysis of NRPS and PKS pathways can accurately 
predict product scaffolds, many other classes of enzymes still need more experimental 
characterization to reach this level of knowledge. However, this body of work demonstrates 
how the characterization of a single enzyme can lead to a broader understanding of an entire 
class of enzymes with the aid of computational tools.  
 
Figure 1.3 – Example domains and reactions of nonribosomal peptide synthetases (NRPS) 
and polyketide synthases (PKS). The substrates are covalently linked to the proteins through 
the phosphopantetheine (Ppant) arm. The domains of the NRPS pathway are: adenylation 
(A), thiolation (T), and condensation (C). The domains of the KPS pathway are: 
acyltransferase (AT), acyl carrier protein (ACP), and keto-synthase (KS). 
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Bioinformatic analysis for most enzymes in secondary metabolism is still limited. 
While software such as BLAST is able to predict the enzyme class and cofactors, the native 
substrates and chemical transformations are usually difficult to predict. For example, in the 
mannopeptimycin pathway the mppP gene was predicted to encode a PLP (pyridoxal 5’-
phosphate)-dependent aminotransferase.22 However upon in vitro analysis of the enzyme, 
MppP was actually shown to act as an ornithine hydroxylase, which was a novel function for 
a PLP-dependent enzyme.23,24 The characterization of MppP was then used to identify a 
homologue that performs similar chemistry within a different cluster.25 The example of 
MppP highlights that each experimental characterization of an enzyme with unknown 
function helps aid the characterization of additional enzymes and the global understanding of 
enzymatic pathways. However, to accurately predict substrates and products similar to the 
NRPS and PKS systems using bioinformatics, many more enzymes of each class need to be 
characterized. Especially in secondary metabolism, many predicted proteins do not have 
close homologues that have been characterized, which can lead to incorrect functional 
assignments. Currently, the limitation of bioinformatically predicted functions from genomic 
data necessitate in vitro analyses to elucidate most natural product biosynthetic pathways. 
Discovering the products of secondary metabolite gene clusters 
 The second step in the workflow for characterizing the enzymes of secondary 
metabolite natural product pathways is identifying the natural product of the proposed gene 
cluster being studied (Figure 1.2).  To understand the functions of a class of enzymes in 
secondary metabolism one must first identify and characterize their native functions. 
Although, this is complicated by the fact that enzymes from the same class can perform a 
variety of chemical reactions using the same cofactors. Thus, without any information about 
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the native pathway, discovering the function of enzymes can be a difficult task. Therefore, as 
shown in figure 1.2, the most common starting point in characterizing the function of an 
enzyme from a gene cluster is the isolation and characterization of the final product of the 
pathway, which can be achieved using a variety of molecular biology and analytical 
chemistry techniques.  
The isolation of microbial natural products is made difficult by the fact that the 
majority of these natural product pathways are not expressed under typical laboratory 
conditions. While some researchers have found that modifying culture conditions26–28 or 
including multiple strains in a single culture can change the expression pattern of 
bacteria,29,30 most investigators rely on molecular biology to identify natural products from 
target gene clusters. The two most common techniques are heterologous expression and gene 
knockouts. Each of these techniques has its advantages and disadvantages, and when used 
together can elucidate the final products of pathways as well as important intermediates.  
Most native producers of natural products are difficult to work with in the laboratory. 
They either do not grow under laboratory settings, have low levels of expression of the 
desired pathway, or are not genetically tractable. Therefore, heterologous expression is used 
to overcome these obstacles by expressing the target cluster in an organism with desired 
traits. The most common strains used for heterologous expression are Escherichia coli for 
bacterial gene clusters and Saccharomyces cerevisiae for fungal gene clusters, since these are 
both well studied and compatible with most genetic manipulation techniques.31 These strains 
can be transformed using plasmids or cosmids that contain the entire biosynthetic gene 
cluster. Additionally, during the cloning process the gene cluster can be put under the control 
of strong or inducible promoters in order to overexpress the enzymes of the pathway, leading 
9 
to greater production of the final product. The DNA assembler method is able to introduce 
promoters before each gene of a cluster in a single step to ensure equal overexpression of 
each gene.32,33 Once the heterologous host is transformed with the desired gene cluster, 
culture extracts can be analyzed by NMR or LC-MS to detect new products and 
intermediates. For most pathways, heterologous expression leads to greater production of 
natural products than in the native organism, although some natural products are still not 
produced at all. These pathways may require substrates or cofactors not normally produced in 
the heterologous host, which will prevent the biosynthesis of the final product.34 Thus the 
choice of heterologous host is crucial, and the decision is dependent on the enzymes of the 
pathway being expressed. Although heterologous hosts are useful for characterizing gene 
clusters, in certain circumstances it can be more beneficial to study pathways using 
knockouts in the native host. 
When the native producer is genetically tractable, gene deletion and inactivation are 
powerful techniques to connect a gene cluster to its respective natural product or vice versa. 
In both cases, the function of the encoded protein is disrupted to prevent the production of 
the natural product. One common way to inactivate the genes responsible for the synthesis of 
a target natural product is transposon mutagenesis. Transposon mutagenesis randomly 
disrupts genes in the native producer thereby creating a library of mutants, each with a 
different gene inactivated.35 The bottleneck in transposon mutagenesis is identifying the 
mutants that have the target pathway inactivated, which is often identified by phenotypic 
screens of thousands of mutants.35,36 After identifying the mutants that no longer produce the 
target compound, sequencing of the transposon insertion also identifies the sequence of the 
gene that has been disrupted, thus elucidating a gene necessary for its biosynthesis.35 
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Alternatively, genetic knockouts can be a more efficient way of identifying the product of a 
target gene cluster. The first step of this two-step knock-out process utilizes homologous 
recombination; by creating plasmid vectors that can insert themselves into targeted locations 
in the bacterial genome by incorporating homologous regions of the targeted genomic 
sequence that have been amplified by PCR.37,38 Then a second round of homologous 
recombination removes the plasmid along with a portion of the gene cluster leaving either a 
selective marker for screening or no insert, to reduce polarization effects on the surrounding 
genes.37 By knocking out targeted genes in a cluster and then performing comparative 
metabolomics between the wild type and knock out strains, potential natural products can be 
identified.39 Also, when genes responsible for late stage modifications are knocked-out, 
intermediates of the pathway can accumulate for easier detection. Together these two 
techniques, transposon mutagenesis and genetic knockout, can be extremely useful molecular 
biology techniques to connect gene clusters and their natural products, an important step in 
identifying the specific proteins worth further characterization.  
In vitro characterization of biosynthetic enzymes 
 Once a gene cluster is shown to produce a natural product, the next step is the 
characterization of the enzymes in the biosynthetic pathway (Figure 1.2). While many 
techniques have been used to characterize enzymes, the most definitive experiments are in 
vitro assays performed using purified proteins. By reproducing enzyme activity outside of 
cells, the presence and concentration of each individual component can be systematically 
controlled, and the necessary cofactors and substrates can be identified. Characterizing 
multiple enzymes of a natural product pathway in this way reveals the biosynthetic logic of 
converting simple building blocks into complex scaffolds. However, even when the purified 
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enzymes are active in vitro, the detection and identification of resultant products can still 
prove difficult.  
Since the first observance of fermentation in the absence of cells in 1894,1 the use of 
in vitro assays to characterize enzyme function has become increasingly common. Most 
initial methods for detecting enzyme activity were absorbance or radioactivity based. For 
example, as early as 1946, phosphatase activity has been measured using p-nitrophenyl 
phosphate, a non-native, colorless substrate that generates a yellow color after phosphate 
cleavage that can be readily detected using UV-Vis absorbance.40 While the use of non-
native substrates has been useful in characterizing some enzymes, many enzymes are not 
capable of reacting with non-native substrates. As an alternative, many in vitro assays have 
been developed that measure byproduct formation in order to detect activity. For example, 
peroxidase enzymes create reactive oxygen species from hydrogen peroxide, which in turn 
are able to react with exogenously added reagents sensitive to oxidation. These  added 
reagents, such as 3-methyl-2-benzothiazolinone hydrazine and 3-(dimethylamino)benzoic 
acid, produce colored products when oxidized that can be used to follow the progress of the 
enzyme reaction using UV absorbance.41 Although these byproduct detection strategies allow 
for fast analysis and activity detection of enzyme activity, the use of non-natural substrates 
and the indirect measurement of enzyme activity are significant limitations of these 
approaches. In recent years, advancements in liquid chromatography-mass spectrometry (LC-
MS) and nuclear magnetic resonance spectroscopy (NMR) methods have allowed for direct 
detection of the products of enzymatic reactions. 
Detecting enzymatic products directly eliminates the need for additional non-native 
reagents that may interfere with enzyme function during in vitro reactions. Entire pathways 
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have been reconstituted in one pot assays in vitro, where reaction intermediates as well as the 
final products can be detected by LC-MS.42–45 Additionally, by sequentially removing 
individual cofactors and enzymes from the assay, researchers can determine the necessary 
components of each chemical transformation. This approach allows for the elucidation of the 
roles of each enzyme in a pathway from one set of assay conditions. Even in cases where 
detection of products is difficult, the addition of derivatizing agents can improve both 
product/byproduct separation by LC, and detection by MS. Especially for small polar 
compounds, such as amino acids, derivatization allows for better detection of low abundance 
products.46,47 For example, O-phthalaldehyde has been used to derivatize primary amines to 
improve separation on reverse phase columns and give compounds UV absorbance.46 Also, 
derivatizing agents are typically added after the enzymatic assays are quenched, so that they 
do not interfere with enzyme activity. Additionally, chemical probes can be used to release 
covalently bound intermediates from enzymes to allow the characterization of individual 
steps and reaction intermediates of a single enzyme. Most commonly, this strategy has been 
utilized for NPRS and PKS systems, as the substrates of these pathways are covalently bound 
to the enzymes and undergo multiple sequential reactions before the release of the final 
product. For example, the nucleophile cysteamine mimics the natural phosphopantetheine 
arm of PKS and NRPS systems (Figure 1.4) and was used as a chemical probe to release 
intermediates that were covalently linked to the PKS CalE8 of the calicheamicin pathway. 
CalE8 was heterologously expressed in E. coli and purified with intermediates covalently 
linked, which were cleaved by cysteamine for analysis by LC-MS.48 Essentially chemical 
reactions that occurred in vivo were able to be identified using a chemical probe in vitro. In 
addition to being useful in characterizing enzyme function, chemical probes and substrate 
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analogues have also been useful tools in understanding the chemical mechanism of enzyme 
reactions. 
 
Figure 1.4 – Comparison of the chemical probe cysteamine and the posttranslational 
modification phosphopantetheine. 
Elucidating Enzyme Mechanisms using Chemical Probes 
In order to fully characterize an enzyme, it is also necessary to determine the 
chemical mechanism of the reaction. While the products and byproducts of enzyme reactions 
can be observed by LC-MS, often there are multiple reasonable chemical mechanisms by 
which those products can be produced. Therefore, further studies are necessary to determine 
which mechanism is actually correct. Elucidating an enzyme mechanism allows researchers 
to understand the possibilities and limitations of an enzyme as a biocatalyst for organic 
schemes. One of the oldest and most common techniques to probe the mechanism is to use 
isotope-labeled substrates and cofactors to track the movement of atoms through the 
reactions. 
As early as 1947 isotope-labeled substrates were used by Doudoroff et al. to observed 
the exchange between radioactive 32P enriched inorganic phosphate and the unlabeled 
phosphate of glucose-1-phosphate by sucrose phosphorylase.49 By observing the rapid 
exchange of the radioactive 32P into glucose-1-phosphate, it was determined that there must 
be a glucosyl-enzyme intermediate. While many of the first isotope labeling studies used 
radioactive isotopes, more recent studies use stable isotopes and detect exchange of atoms 
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using MS. For example, the source of the oxygen for the hydroxylation of arginine performed 
by MppP was determined by separately testing activity in the presence of either 18O2 or 
H2
18O. Only in the presence of H2
18O was 18O incorporation into the product ever observed, 
meaning the hydroxyl in the product was from water, and not an activated oxygen species as 
previously hypothesized.23 A similar method can also be used to determine regioselectivity of 
modifications, and allows for the detection of mechanistic steps that occur but are not present 
in the final product. One of the first examples used ATP labeled with 18O at the phosphate 
linking oxygens to detect where cleavage of ATP occurs in the glutamine synthetase 
mechanism. By using differentially labeled isotope substrates, the reaction was shown to 
proceed through the addition of inorganic phosphate onto glutamate, since cleavage of ATP 
occurred between the beta and gamma phosphates before ATP regeneration.50 Similarly, the 
oxidative decarboxylation activity of the nonheme oxidase UndA was revealed using 
differentially labeled lauric acid substrates. Substrates enriched with either deuterium or 13C 
were used to definitively determine which atoms were lost through catalysis to understand 
the complex mechanism involving radical chemistry.51 In addition to isotope enriched 
substrates, non-natural substrates can be used to further dissect the chemical transformations 
that occur. 
By using non-native substrates that have altered functional groups, the course of an 
enzymatic reaction can be slightly changed to give more information about the chemical 
mechanism. Even in complex radical S-adenosyl-L-methionine (SAM)-dependent 
mechanisms non-native substrates have been used. In the biosynthesis of molybdopterin, 
MoaA is a radical SAM enzyme that uses GTP as a substrate. By using both chlorinated and 
deoxy analogues of GTP, products with different ring formations were observed due to the 
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trapping of early and late stage radical intermediates. The insight gained from the two non-
native products allowed researchers to propose a mechanism for the native function of 
MoaA.52 Using chemical probes and unnatural substrates to understand radical enzyme 
mechanisms truly shows the utility of these types of experiments. With clever experimental 
design, and access to analogues of substrates and intermediates, researchers can now 
understand enzyme functions down to the chemical mechanism, which unlocks new 
opportunities for using enzymes in future synthetic applications.  
Summary and Perspectives  
Enzymes from secondary metabolite pathways perform some of the most diverse and 
interesting chemistry found in nature and many have the potential to be useful in establishing 
efficient and green alternatives to standard organic chemical syntheses. The diversity of 
products synthesized by these enzymatic pathways exemplifies the wide range of chemical 
functional groups that are synthesized in secondary metabolism (Figure 1.1). Importantly, 
from a research perspective, the biosyntheses of several of these functional groups are still 
unknown because many of the enzymatic pathways that produce them are still 
uncharacterized. Even with the increase of genomic guided studies it is difficult to accurately 
predict activities for multiple enzyme classes. The exhaustive work done characterizing 
NRPS and PKS systems has led to the development of several bioinformatic prediction 
models, but even the these systems are limited to the canonical NRPS and PKS pathways.8 
Thus, the characterization of additional enzymes in PKS and NRPS pathways, as well as 
other enzymatic classes, will be needed to expand the scope of information used to support 
homology searches to lead to better predictive functions for future enzyme characterization 
studies. Also, characterizing additional classes of enzymes will expand the biocatalytic 
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toolbox available for semi-synthetic routes. Being able to employ well-characterized 
enzymes to perform difficult chemistry with almost absolute stereochemistry represents a 
green alternative to typical organic synthesis reactions. The work described herein leverages 
the iterative cycle shown in Figure 1.2 to advance the field of characterizing secondary 
metabolite pathways in multiple ways. First, the characterization of an enzyme pair that uses 
a novel strategy to produce an NRPS/PKS hybrid antibiotic (Chapter 2).  Second, the use of 
new methods to study non-canonical NRPS pathways (Chapter 3). And finally, identification 
of multiple products from a single gene cluster and insights into the biosynthesis of these 




CHAPTER 2: CHARACTERIZATION OF THE LATE STAGE MODIFICATION 
ENZYMES IN THE BIOSYNTHESIS OF THE HYBRID ANTIBIOTIC 
THIOMARINOL 
Introduction 
In recent years, the increasing prevalence of antibiotic resistant infections has 
underscored the critical need for the development of new antibiotics.53,54  While significant 
efforts have been put into searching for novel molecular scaffolds that are able to inhibit 
unexplored cellular targets, the generation of hybrid antibiotics represents an alternative 
approach to this growing problem. Hybrid antibiotics combine the antibiotic warheads from 
two different molecules into one compound via covalent linkages. These hybrid antibiotics 
tend to have greater bioactivity compared to each individual component, and although 
combination drug therapies are frequently employed in cancer treatment, such combination 
treatments are rare in antimicrobial therapies. It is postulated that hybrid antibiotics would 
reduce the likelihood for resistance to develop as well as expand the spectrum of susceptible 
bacteria over that of either individual component.55,56 However, there are potential challenges 
to generating these molecules synthetically. For example, it is possible that the covalent 
linker used to combine the two antibiotics will hinder the ability of one or both of the 
warheads to bind to their targets. Additionally, if the targets of each warhead are not located 
in the same cellular compartment, the effective concentration of each warhead would be 
reduced.57,58 
 While these are significant issues for synthetically generated hybrid antibiotics, 
naturally occurring molecules have been refined by nature to minimize these issues. One 
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example is thiomarinol, which is produced by Pseudoalteromonas sp. SANK73390. 
Thiomarinol is a combination of marinolic acid, which is structurally similar to pseudomonic 
acid A (PAA), the active molecule of the FDA-approved drug mupirocin, and holothin, 
which belongs to the dithiolopyrrolone (DTP) class of antibiotics.59 PAA is known to inhibit 
bacterial isoleucine-tRNA synthetase and thereby prevent protein synthesis,60 but the 
mechanism of action of holothin is not as well characterized. Holomycin, the acetylated form 
of holothin, is thought to inhibit bacterial transcription,61,62 and recently the method of action 
was found to be through the disruption of metal homeostasis, and inhibition of a subset of 
metalloenzymes.63 Interestingly, the isoleucine-tRNA synthetase target of PAA contains zinc 
in the active site of one of its domains.60 Even though individually these antibiotics affect 
different pathways, the combined hybrid is more effective against a variety of bacterial 




Figure 2.1 – Structure of thiomarinol analogues and components and the thiomarinol gene 
cluster. A) Structures of thiomarinols, pseudomonic acids, and dithiolopyrrolones. B) Gene 
cluster for thiomarinol. Open arrows indicate open reading frames (ORFs) with homology to 
the mupirocin pathway; blue ORFs are homologous to DTP biosynthetic genes; black ORFs 
are unique to the thiomarinol pathway; the red ORFs, TmlU and HolE, are the targets of this 
study and have counterparts in the mupirocin and holomycin pathways, respectively. 
 The gene cluster responsible for thiomarinol production from Pseudoalteromonas sp. 
SANK73390 was identified via whole genome sequencing of the producing bacterium. The 
cluster is harbored by a 97 kb cosmid that contains polyketide synthase (PKS) genes 
responsible for the production of marinolic acid, and nonribosomal peptide synthetase 
(NRPS) genes responsible for the production of holothin. Previous genetic knockout studies 
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have identified the enzyme TmlU (WP_013933291.1) as a necessary component in linking 
the two antibiotic warheads of thiomarinol. When the gene tmlU is deleted, thiomarinol is no 
longer produced, and instead both marinolic acid and holothin are produced.64 Previous 
studies have also identified TmlU as a putative amide-ligase due to its homology to NovL 
(20.7%), CouL (21.1%), and SimL (18.5%), amide-ligases found in gene clusters responsible 
for the biosynthesis of aminocoumarin-containing antibiotics.65–67 Each of these 
characterized amide ligases activate a carboxylic acid by creating an acyl-AMP intermediate 
before an amine attacks the activated ester to create an amide bond, however, this mechanism 
has not been proven for TmlU. 
Instead, it is possible that TmlU work through a different mechanism. The 
thiomarinol cluster also contains HolE (WP_013933302.1), which shares homology with 
HlmA of the holomycin pathway from Streptomyces clavuligerus.68,69  In holomycin 
synthesis, HlmA acetylates the amine of holothin to create holomycin using acetyl-CoA as a 
substrate.68 The gene encoding HolE is found near the NRPS and tailoring genes responsible 
for holothin production, but was not predicted to have a specific role in holothin or 
thiomarinol biosynthesis; and instead it was thought to be responsible for only the 
background acylation of holothin. Here we considered the possibility that HolE may work 
with TmlU in linking together the two antibiotic warheads encoded by this cluster, which 
would be a novel strategy to produce NPRS/PKS hybrids in nature.  
Materials and Methods 
TmlU Expression and Purification 
N-His TmlU was expressed in BAP1 E. coli cells in LB Miller media containing 50 
µg/mL kanamycin sulfate.  All chemicals were purchased from Fisher Scientific unless 
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otherwise noted.  The cultures were grown at 37 °C and when the OD600 reached 0.6 they 
were cooled on ice, induced with 0.5 mM IPTG and grown for 18–20 hours at 16 °C.  Unless 
otherwise stated, all purification steps were carried out at 4 °C or on ice.  Cells were pelleted 
by centrifugation at 3000 𝑥 g for 30 minutes.  Pellets were resuspended in Buffer A (50 mM 
MOPS, 500 mM NaCl, 20 mM imidazole, 10 mM MgCl2, 1 mM tris(2-carboxyethyl) 
phosphine (TCEP), 10% glycerol, pH 7.5) that contained complete EDTA-free protease 
inhibitor cocktail (Roche).  The resuspension was lysed using a Fisher Scientific Sonic 
dismembrator model 500 (1.5 minute cycles of 30% amplitude with pulse on 0.5 seconds and 
pulse off 1.5 seconds) and centrifuged for 30 minutes at 34,500 𝑥 g at 4 °C.  The supernatant 
was filtered using a 0.45 µm filter, and then applied to a GE HisTrap HP Ni column which 
was equilibrated in Buffer A. His-tagged TmlU was eluted using a linear gradient of Buffer B 
(50 mM MOPS, 500 mM NaCl, 250 mM imidazole, 10 mM MgCl2, 1 mM TCEP, 10% 
glycerol, pH 7.5).  Pooled fractions were concentrated with a Millipore centrifugal filter with 
a 10 kDa molecular weight cut off at 3500 𝑥 g to a final volume of 2.5 mL.  The sample was 
desalted with a PD-10 column pre-equilibrated in Buffer C (20 mM potassium phosphate, 
400 mM NaCl, 5% glycerol, pH 7.0).  The flow-through was then applied to GE HiLoad 
16/600 Superdex 200 pg column that was equilibrated with Buffer C.  The pooled fractions 
were concentrated using a Millipore centrifugal filter at 3500 𝑥 g to a concentration of 2–5 
mg/mL.   
HolE Synthesis and Subcloning 
The complete HolE gene was synthesized by Life technologies in a pMA-T plasmid. 
DH5α chemically competent cells were transformed with the constructed plasmid and grown 
overnight on LB ampicillin plates (100 µg/mL) at 37 °C.  A single colony was picked and 
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grown overnight in a culture volume of 5 mL LB with 100 µg/mL ampicillin.  Plasmid was 
isolated from the culture using the Zyppy Plasmid Miniprep Kit.  Isolated pMA-T-HolE and 
pET28a were digested with NdeI and XhoI at 37 °C for 3 hours then separated on an agarose 
gel.  The resulting bands of digested HolE and pET28a were excised and extracted using the 
Zymoclean DNA Recovery Kit. The purified HolE and pET28a digested fragments were 
combined in a 1:3 vector:insert molar ratio.  This mixture was ligated overnight using T4 
DNA Ligase at 4 °C.  The ligation product was cleaned and purified by butanol precipitation 
and resuspended in 10 µL of distilled water, which was used to transform Rosetta chemically 
competent cells. The pET28a-HolE plasmid was isolated from the transformed Rosetta cells 
as above and confirmed by analytical digestion by NdeI and XhoI. 
HolE Expression and Purification 
HolE expression was carried out similarly to TmlU except that protein expression was 
induced with 0.1 mM IPTG.  The same purification procedure was followed using modified 
Buffer A (20 mM potassium phosphate, 500 mM NaCl, 50 mM imidazole, 10 mM MgCl2, 
10% glycerol, pH 7.5) and modified Buffer B (20 mM potassium phosphate, 500 mM NaCl, 
500 mM imidazole, 10 mM MgCl2, 10% glycerol, pH 7.5). 
In vitro Reconstitution of TmlU and HolE Activities 
Each reaction was initiated by addition of TmlU and/or HolE to final concentrations 
of 1–5 µM in 20 mM potassium phosphate pH 7.5. The remainder of the assay components 
were 2 mM MgCl2, 1 mM ATP, 1 µM CoA, 0.1–1 mM of acyl carboxylic acid substrate, and 
0.1–1 mM of amine substrate.  Enzymatic reactions were incubated for 5–20 minutes at room 
temperature and quenched by adding an equal volume of acetonitrile, inverting and 
incubating at −20 °C for at least 20 minutes.  Samples were spun at 20800 𝑥 g for 10 minutes 
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to remove protein precipitant. The supernatants were diluted 2-fold and analyzed using 
Agilent Technologies 6520 Accurate-Mass Q-TOF LC-MS.  Samples were separated using a 
Kinetex 2.6 µm C18 150 mm column. Solvent A consisted of 0.1% formic acid in water, and 
solvent B consisted of 0.1% formic acid in acetonitrile. Positive ion mode ESI mass 
spectrometry was carried out using the following parameters: gas temperature 300 °C, drying 
gas 10 L/min, nebulizer 45 lb/in2, fragmentor 175 V, skimmer 65 V.   
TmlU Kinetics  
Solutions were prepared from the same stock solutions as in vitro reconstitution 
described above. Each reaction was initiated by addition of TmlU to a final concentration of 
5 nM in 20 mM potassium phosphate at pH 7.5. The rest of the assay components were 10 
µM HolE, 2 mM MgCl2, 1 mM ATP, 1 µM CoA, 2–100 µM of PAC or PAA or 0.1–5 mM 
octanoic acid, and 500 µM 3-aminocoumarin. Aliquots of the reaction were added to an 
equal volume of acetonitrile every three minutes for PAC and PAA, and every 5 minutes for 
octanoic acid. The samples were incubated at room temperature for 20 minutes and spun at 
20800 𝑥 g for 10 minutes to remove protein precipitants. The samples were then analyzed 
undiluted by LC-MS as described above. 
HolE Acyl-CoA Substrate Scope 
Each reaction was initiated by addition of HolE to a final concentration of 5 µM in 20 
mM potassium phosphate at pH 7.5. The rest of the assay components were 2 mM MgCl2, 
200 µM Acyl-CoA substrate, and 100 µM holothin. Samples were diluted 2-fold and 
analyzed as described above. These enzymatic reactions were incubated for 10 minutes at 




TmlU acts as an CoA-ligase and HolE acts an amide-ligase to produce thiomarinol 
The N-terminal His-tagged form of TmlU was overexpressed and purified to > 95% 
purity. When pseudomonic acid C (PAC) and holothin were incubated with TmlU and ATP, 
no product was formed. Further examination of the thiomarinol and mupirocin biosynthetic 
pathways showed that TmlU shared 14% homology with MupU, which suggested that TmlU 
may act as a CoA-ligase to make an activated intermediate that another gene in the cluster 
would use as a substrate. The putative amide ligase HolE was tested with TmlU, because it is 
also found in the thiomarinol gene cluster, and its role in the biosynthesis of thiomarinol had 
yet to be identified. When both TmlU and HolE were incubated with PAC, holothin, ATP, 
and CoA, the product PAC-holothin was detected using LC-MS (Figure 2.2A). The product 
had identical retention time and mass to the synthetic standard (Figure 2.2B), and removal of 
ATP, CoA, or either enzyme from the assay abolished PAC-holothin production. To confirm 
that TmlU and HolE were following the proposed mechanism, the PAC-AMP and PAC-CoA 
intermediates were identified using LC-MS (Figures 2.2B and D). The PAC-CoA complex 
would often be found either bound to either Al3+, or Fe3+ in acidic conditions, or Na+ and K+ 
in basic conditions. However, under neutral conditions the [M + H]+ species was observed 
(Figure 2.2B).  
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Figure 2.2 – Enzymatic production of PAC-holothin, a thiomarinol analogue, in vitro by 
TmlU and HolE. A) In vitro reconstitution of TmlU and HolE activity compared to a PAC-
holothin synthetic standard and controls. B) Mass spectrum of PAC-CoA generated by TmlU 
(calculated [M+H]+, 1234.4155). C) Mass spectrum of PAC-holothin generated 
enzymatically by TmlU and HolE (calculated [M+H]+, 639.2768). D) Mass spectrum of 
PAC-AMP generated by TmlU (calculated [M+H] 814.3634) 
TmlU has strict substrate specificity, while HolE is a promiscuous amide-ligase 
After confirming the mechanisms of TmlU and HolE, we tested the substrate 
specificity of each enzyme. TmlU was found to be fairly selective and had only minor 
activity with substrates other than PAC and PAA (Figure 2.3A). However, HolE showed a 
greater promiscuity and demonstrated high levels of activity using a variety of acyl-CoA 
substrates, and moderate activity using amines that contained an adjacent ketone (Figure 
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2.3B and C). After determining the substrate specificity of each enzyme, the kinetics of each 
were probed. However, when HolE was incubated with high concentrations of holothin, 
HolE showed reduced activity, preventing determination of Km and kcat values. Kinetic 
studies of TmlU to produce the acyl-CoA product were probed by coupling this activity with 
an excess of HolE and 3-aminocouamrin in order to form the acyl-aminocoumarin product. 
Testing the kinetics of PAC found Km and kcat to be 6 ± 1 µM 3.2 ± 0.1 s
-1 respectively 
(Figure 2.4A). Experiments using PAA as the substrate yielded similar values, Km of 5.2 ± 
0.5 µM and kcat of 3.0 ± 0.1 s
-1 (Figure 2.4B), but the affinity and efficiency of TmlU to 








Figure 2.3 – Substrate promiscuity of TmlU and HolE. A) Incorporation of carboxylic acids 
into thiomarinol by 5 µM TmlU in the presence of saturating concentrations of HolE and 
holothin. Activity was measured by the formation of the acyl-holothin products at 360nm and 
normalized to activity with PAC as substrate. [a] 1 µM TmlU was used in this assay. [b] 2,4-
DDA: (2E,4E)-2,4-dodecadienoic acid. [c] 2,4-DA: (2E,4E)-2,4-decadienoic acid. B) 
Activity of HolE with acyl-CoA derivatives as substrates to generate acyl-holothin products. 
PAC-SNAC - N-acetyl cysteamine pseudomonic acid C. C) Activity of HolE with different 
amines as substrates. PAC-CoA was generated by TmlU. Activity was measured by 
integration of ion intensities in mass spectra. 
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Figure 2.4 – Kinetic measurement of TmlU with different substrates. A) PAC, Km=6±1 µM 
and kcat=3.2±0.1 s
-1. B) PAA Km=5.2±0.5 µM and kcat=3.0±0.1 s
-1. C) Octanoic acid, 
Km=0.5±0.1 mM and kcat=(5.0±0.3) x 10
-3 s-1. 
HolE is unable to produce a PAC-aminopenicillin hybrid 
6-aminopenicillinic acid belongs to the beta-lactam family of antibiotics that inhibit 
bacterial cell wall biosynthesis, and we proposed it would be a substrate for HolE due to the 
similarities between 6-aminopenicillinic acid and holothin. However, when we included 6-
aminopenicillinc acid in assays with HolE, we detected the production of the hydrolyzed 
product but not the PAC-6-aminopenicllin hybrid (Figure 2.5). Thus, the beta-lactam family 
of antibiotics appears to be incompatible with the HolE and TmlU assay to make new PAC 
containing hybrid antibiotics. 
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Figure 2.5 – HolE degrades 6-aminopenicillanic acid and is unable to form PAC analogue. 
A) Extracted ion chromatograms of the hydrolyzed 6-aminopenicillanic acid product, 
[M+H]+ 235.0747. B) Scheme of cleavage of 6-aminopenicillanic acid by HolE. 
Discussion 
Using in vitro reactions, we tested the hypothesis that TmlU acted as an amide ligase, 
and was the sole enzyme needed to link monic acid and holothin to create thiomarinol. In all 
in vitro reactions pseudomonic acid C (PAC) was used as a substrate instead of the native 
substrate marinolic acid, since PAC is much easier to synthesize and it only differs from the 
native substrate by one carbon in the acyl acid chain. When TmlU was incubated with 
holothin, PAC, and ATP, no PAC-holothin was detected, suggesting that TmlU is not an 
amide ligase and may instead have a different function. The presence of the putative amide 
ligase HolE in the thiomarinol cluster suggested that both HolE and TmlU may work together 
to produce thiomarinol. We hypothesized that TmlU may be an acyl-CoA ligase due to its 
homology to MupU, and that HolE would use an activated PAC-CoA intermediate for the 
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production of PAC-holothin (Figure 2.6). Incubation of HolE and TmlU with PAC, holothin, 
ATP, and CoA produced PAC-holothin. The identity of PAC-holothin was confirmed by 
comparing the elution time and m/z to a synthetic standard (Figure 2.2A and D). Removing 
HolE from the in vitro assay abolished PAC-holothin formation, but PAC was still consumed 
by TmlU, and the PAC-CoA intermediate was identified and confirmed by MS2 (Figures 
2.2B). Removal of CoA from the assay also resulted in the loss of PAC-holothin formation, 
and instead there was a slight accumulation of the PAC-AMP intermediate (Figure 2.2D). 
When either TmlU or ATP were not present there was no consumption of PAC; all of which 
supports the mechanism that TmlU acts as an acyl-CoA ligase to produce a PAC-CoA that 
HolE then uses as a substrate to create PAC-holothin (Figure 2.6).  
 
Figure 2.6 – Scheme of TmlU and HolE production of thiomarinol.  
After the functions of both enzymes were determined, we investigated the kinetics of 
TmlU. The formation of acyl-CoA products by TmlU were measured in the presence of 
excess ATP and CoA. When PAC was used as substrate, TmlU had a Km of 6 ± 1 µM and a 
kcat of 3.2 ± 0.1 s
-1 (Figure 2.4A). PAA had very similar values for Km and kcat, (Figure 2.4B) 
suggesting that TmlU is not responsible for the selectivity of P. spp. SANK73390 to produce 
thiomarinol without the epoxide, even though the corresponding pseudomonic acid is the 
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preferred product of the mupirocin pathway. Instead, we hypothesized that the thiomarinol 
pathway is missing the tailoring enzymes responsible for epoxide formation in PAA. We also 
tested the ability of TmlU to activate octanoic acid, to test the importance of the monic acid 
portion of PAC on TmlU activity. The catalytic efficiency (kcat/Km) of octanoic acid was 
50,000-fold less than PAC or PAA, indicating that monic acid is necessary for greater TmlU 
activity (Figure 2.4C). To test if monic acid is able to activate TmlU by inducing a 
conformational change or if monic acid is important for substrate recognition, we measured 
the formation of octanoyl-CoA in the presence and absence of methyl monic ester. No 
difference in activity was observed, which indicates that interaction between monic acid and 
TmlU are involved in substrate recognition and not TmlU activation. We were unable to 
perform similar kinetic analysis of HolE because the native substrate holothin displayed 
inhibitory activity against HolE at concentrations above 20 µM.  
The substrate specificity of each enzyme was investigated to test the potential ability 
of the TmlU/HolE system to produce new hybrid antibiotic molecules. In general, TmlU was 
found to be more selective than HolE. TmlU was only able to activate fatty acid chains and 
did not tolerate the presence of additional functional groups (Figure 2.3A). On the other 
hand, HolE was able to utilize many different acyl-CoA substrates, most with over 80% 
conversion, and only two of the acyl-CoA’s tested had zero activity (Figure 2.3B). 
Additionally, HolE had significantly lower activity when incubated with the truncated N-
acetyl cysteamine (SNAC) analogue of PAC-CoA that is missing the adenosine moiety, 
which suggests that the CoA portion is important for substrate recognition by HolE. To 
investigate amine specificity of HolE, a variety of scaffolds were tested with HolE, and the 
four compounds with greatest activity contained a cyclic structure with a carbonyl adjacent to 
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a primary amine (Figure 2.3C). The importance of the ring for substrate recognition was 
highlighted by the conversion of phenylalanine methyl ester being significantly better than 
that of glycine. A variety of aniline derivatives had slight activity, but all were far less than 
ketone containing substrates and would require modifications of HolE to make substantial 
amounts of product. Due to the inherent promiscuity of HolE, the enzyme pair of TmlU and 
HolE could be a useful system to create multiple non-natural PAC and PAA hybrid 
molecules, potentially with new bioactivities. Unfortunately, our attempt to use 6-
aminopenicillanic acid as a substrate for HolE did not lead to hybrid formation, and instead 









Figure 2.7 – Mechanism of thiomarinol production by TmlU and HolE compared to 
assembly-line tethered mechanisms to create PKS/NRPS hybrids. A) The condensation 
domain of a NRPS directly adds a PKS product to a growing peptide chain. B) A stand-alone 
transglutaminase-like domain (TGH) catalyzes the transfer between tethered PKS and NRPS 
products in the biosynthesis of andrimid.70 C) Tailoring enzymes TmlU and HolE create a 
NRPS/PKS hybrid from released products of discrete PKS and NRPS pathways. KS: 
ketosynthase, AT: acyltransferase, ACP: acyl carrier protein, C: condensation domain, A: 
adenylation domain, PCP: peptidyl carrier protein. 
Conclusion and Future Directions 
The thiomarinol gene cluster is an interesting evolutionary product that appears to 
have combined two separate antibiotic pathways to produce a single hybrid antibiotic. The 
roles TmlU and HolE have been repurposed from the biosynthesis of either their respective 
PKS or NRPS pathways to instead catalyze the linkage of two bioactive molecules to 
produce thiomarinol, which has increased bioactivity and reduced antibiotic resistance. TmlU 
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and HolE utilize a novel strategy to produce NRPS/PKS hybrids, which has the advantage of 
using substrates that are free in solution instead of bound to an NRPS or PKS scaffold 
(Figure 2.7). Since both enzymes act on substrates free in solution, we were able to rapidly 
test various substrates for each enzyme in vitro. HolE was found to be a promiscuous amide 
ligase that was able to accept a variety of acyl-CoA and amine substrates. In this study, we 
were able to use the TmlU/HolE system to link two non-native substrates and create 
completely non-natural products. However, our attempt to create a PAC-penicillin hybrid 
was unsuccessful since HolE degraded the beta-lactam core of 6-aminopenicillanic acid. 
While beta-lactams were not compatible with HolE, it is possible that other amine-containing 
antibiotics could be used to make novel PAC containing hybrid antibiotics with improved 
bioactivity. Currently, the stringent specificity of TmlU limits the variety of acids that 
currently can be utilized to make hybrid molecules, the intrinsic promiscuity of HolE for 
various substrates is a valuable trait for future directed evolution and modification in order to 




CHAPTER 3: CHARACTERIZATION OF NONRIBOSOMAL PEPTIDE 
SYTHETASES BIOSYNTHETIC PATHWAYS USING CYSTEAMINE AS A 
MOLECULAR PROBE 
Introduction 
Two of the most well studied classes of secondary metabolite enzymes are 
nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS). Both classes are 
large modular assembly-line-like enzymes that use a 4’-phosphopantetheine (Ppant) arm to 
covalently tether a growing natural product scaffold to the protein. In canonical NRPS 
pathways, each module will add one amino acid to the growing scaffold. The smallest 
complete module of an NRPS contains 3 domains: an adenylation (A) domain, a thiolation 
(T) domain, and a condensation (C) domain. The A domain activates the amino acid that is 
loaded onto the Ppant arm of the T domain, where the growing peptide chain can be 
elongated by the C domain and/or modified by tailoring enzymes in the pathway.18 Tailoring 
enzymes are separate proteins from the NRPS that modify the natural product scaffold being 
constructed. The roles of tailoring enzymes range from cyclopropanations to hydroxylations 
to oxidation and reductions.71–73 However, elucidating the function of tailoring enzymes is 
challenging since the native substrates for these enzymes are covalently linked to large NRPS 
enzymes. Additionally, previous studies have shown that many tailoring enzymes will not 
modify intermediates free in solution, and instead require the substrate to be linked to the 
native NRPS domain.74 The difficulty of linking intermediates to the T domains of NRPSs 
has prevented the characterization of many classes of  tailoring enzymes, some of which are 
predicted to perform novel chemistry never before seen in nature. While methods have been 
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developed to study tailoring enzymes, these techniques are typically cumbersome and require 
the chemical synthesis of putative intermediates. 
One technique involves loading synthetic intermediates onto truncates of the native 
NRPS enzyme that consist of only a single T domain. This approach has two advantages. 
First, by loading the synthetic intermediate onto the T domain, the substrate more closely 
resembles the native substrate of the tailoring enzyme. Second, because the T domains are 
significantly smaller than intact NRPS enzymes, and the intact T domains, with covalently 
linked substrates and products, can be analyzed by LC-MS. Cryle et al. have successfully 
linked intermediates of the glycopeptide antibiotics onto relevant T domains; however, they 
only applied this approach to the study of one class of antibiotics and primarily focused on 
the modifications catalyzed by p450 enzymes.74–76 The loading of synthetic intermediates 
onto T domains is accomplished by leveraging the substrate promiscuity of the 4’-
phosphopantetheine transferase Sfp (Figure 3.1A), which will recognize a wide range of 
synthetic intermediates covalently linked to coenzyme A (CoA) as substrates (Figure 3.1 B). 
However, the direct synthetic coupling of the synthetic intermediates to CoA has two 
disadvantages: it requires the use of the expensive reagent CoA, and the coupling reaction 
can be hindered by the presence of functional groups on the target intermediate leading to 
low yields of the intermediate-linked CoA-analogue.74,77  
One way to avoid the direct CoA-coupling is to synthesize a pantetheine analogue 
linked to the desired intermediate, and then use the CoA-forming enzymes CoaA, CoaD, and 
CoaE to produce the corresponding intermediate-linked CoA analogues. It has previously 
been shown that the corresponding CoA-analogues can be produced and loaded onto a T 
domain in a one-pot reaction (Figure 3.1 C).78 In addition, this chemo-enzymatic approach 
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has also been used to load more stable amide-containing analogues, which are less 
susceptible to hydrolysis than the natural thioester-containing Ppant substrates. 
  
Figure 3.1 – Schemes to load intermediates onto T domains of NRPSs using the promiscuous 
4’-phosphopantetheine transferase Sfp. A) The native activity of Sfp using coenzyme A 
(CoA) as a substrate B) The loading of a CoA-linked synthetic intermediate onto a T domain 
using Sfp. C) The loading of a pantetheine-linked synthetic intermediate in the presence of 
enzymes CoaA, CoaD, CoaE, and Sfp. R represents the structure of the intermediate being 
loaded. 
The latter chemoenzymatic approach has been used to label T domains with 
fluorescent and chemical tags,78,79 but to our knowledge it has never been used to load a 
biosynthetic intermediate onto a T domain for enzyme characterization. The modular nature 
of the synthesis of pantetheine analogues along with the promiscuity of the CoaA, CoaD, 
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CoaE, and Sfp enzymes mean that this approach is amenable to loading intermediates from 
various enzymatic pathways onto their native T domains. However, a significant barrier to 
using this method for enzyme characterization, especially for large and highly modified 
NRPS products, is the need to chemically synthesize each individual intermediate before 
subsequent enzymatic assays can be performed; and if the predicted substrate is incorrect, a 
new synthetic scheme must be devised and carried out before the next enzymatic assay can 
be performed. To avoid the need to chemically synthesize each intermediate, chemical probes 
can be used to cleave biosynthetic intermediates from NRPS enzymes.   
 While many chemical probes have been used to cleave native intermediates from 
NRPS enzymes, the effectiveness of each chemical probe varies among metabolic pathways. 
The development of a chemical probe method that is effective across most NRPS pathways 
would be a significant step forward for the field. Cysteamine is a chemical probe that was 
shown to successfully cleave intermediates from a PKS system for identification by LC-
MS.48 Cysteamine acts as a nucleophile that is able to cleave the thioester bond that links the 
natural product being synthesized to the PKS enzyme. Since the structure of cysteamine 
mimics the natural Ppant arm of both PKS and NRPS enzyme systems, it was hypothesized 
that cysteamine may be able to access the substrate binding site, and release intermediates 
from both PKS and NRPS. However, to date, the only example in the literature of cysteamine 
being used as a chemical probe to release intermediates from either PKS or NRPS enzymes 
studies the PKS CalE8.  
The PKS CalE8 from the calicheamicin pathway was heterologously expressed in E. 
coli and purified with covalently linked intermediates that were cleaved by cysteamine for 
analysis by LC-MS.48 This study provided a useful starting point for developing a method to 
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cleave intermediates using cysteamine during in vitro assays, which would expand the 
possible utility of cysteamine as a chemical probe. Being able to use cysteamine to cleave 
and identify intermediates produced from in vitro enzymatic assays would provide 
researchers a system for characterizing enzyme pathways and would establish cysteamine as 
a significant improvement versus previous cleavage methods. By controlling which enzymes 
and cofactors are included in the in vitro assays, the activity of both tailoring enzymes and 
the NRPS enzyme can be elucidated. 
Two previously uncharacterized NRPS pathways were studied in this work to 
compare the effectiveness of different methods to characterize tailoring enzymes and non-
canonical NRPS domains. One NRPS pathway that is predicted to have interesting tailoring 
enzymes is encoded by the hlm gene cluster from Streptomyces clavuligerus.68 The hlm gene 
cluster has been shown to be necessary for the production of holomycin, which belongs to the 
dithiolopyrrolone (DTP) family of antibiotics. Members of the DTP family of antibiotics 
have been isolated from both soil and marine bacteria, and DTPs are effective against both 
Gram-positive and Gram-negative bacteria, which makes it a promising starting point for 
modification to create a clinically relevant analogue.80 In studies of the hlm cluster, it has 
been shown that a cysteine dipeptide is loaded onto the T domain of the NRPS HlmE, but the 
chemical reactions necessary to form the aromatic ene-dithiol-disulfide core are unknown 
(Figure 3.2).80 It is predicted that two putative flavoprotein tailoring enzymes, HlmB and 
HlmD, perform the oxidations necessary to produce holomycin, but the activity of these 
enzymes have not been characterized in vitro. In the proposed mechanism of holomycin 
biosynthesis, both enzymes are predicted to catalyze the formation of thioaldehydes, which 
would be a novel chemical transformation for enzymes.68 The hlm gene cluster is just one 
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example of an NRPS pathway that is predicted to perform interesting chemistry, but the exact 
enzymatic reactions are still unknown. 
 
Figure 3.2 – Introduction to the biosynthesis of holomycin. A) The structure of holomycin 
and the domains of the HlmE enzyme. B) Enzymatic modifications convert the cysteine 
dipeptide loaded onto HlmE into holomycin, but the specific biosynthetic steps are still 
uncharacterized.  
In addition to tailoring enzymes, the chemical diversity of NRPS products is 
expanded by noncanonical NRPS enzymes that do not follow the standard A-T-C domain 
structure described previously. One such example is encoded by the amb gene cluster from 
Pseudomonas aeruginosa PAO1, which produces the oxyvinylglycine L-2-amino-4-
methoxy-trans-3-butenoic acid (AMB) (Figure 3.3). The oxyvinylglycines are a family of 
nonproteinogenic amino acids with various substitutions at the side chain ether (Figure 3.3). 
Oxyvinylglycines irreversibly inhibit PLP-dependent enzymes by covalently binding to the 
PLP cofactor.81 The most well studied member of the family is aminoethoxyvinylglycine 
(AVG), which is used commercially as the active ingredient in ReTain® to halt the ripening 
of fruits by inhibiting ethylene biosynthesis in plants.81 AMB inhibits the growth of multiple 
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strains of bacteria, including the human pathogen Staphylococcus aureas.72 Although the 
bioactivities of oxyvinylglycines are potent and varied, few studies have examined the 
biosynthesis of these compounds. In the AMB biosynthetic pathway, the NRPS AmbE 
contains multiple domains that diverge from canonical NRPS logic (Figure 3.3). First, the 
second module of AmbE lacks an A domain to load an amino acid onto the second T domain 
(T2), Second, the C* domain has homology to C domains that are thought to catalyze 
modifications of the scaffold in addition to chain elongation.72 Lastly, the N-terminal Q 
domain has no homology to any characterized NPRS domains and has an unknown role in 
the AMB pathway. The unusual domain architecture of AmbE makes it a challenging 
enzyme to study, but the elucidation of its biosynthetic steps will further the understanding of 





Figure 3.3 – Oxyvinylglycine core and amb gene cluster. A) The structures of L-2-amino-4-
methoxy-trans-3-butenoic acid (AMB) and three other oxyvinylglycines found in nature. B) 
The amb biosynthetic gene cluster that produces AMB. C) The domains of the noncanonical 
NRPS AmbE: adenylation (A), thiolation (T), condensation (C*), thioesterase (TE), O-
methyltransferase (MT), and a domain of unknown function (Q).  
In a previous study the activity of the AMB pathway was reconstituted in vitro,72 but 
many questions still remain. Murcia et al. used a mutant AmbE with an inactivated 
thioesterase (TE) domain, which is normally responsible for the release of products from 
NRPSs. When the AmbE TE mutant, AmbB, AmbC, and AmbD were incubated with 
substrates and cofactors, the assay accumulated an Ala-AMB-Ala tripeptide covalently 
linked to T2 of AmbE.72 However, many questions about the pathway still remained, such as 
the roles of the tailoring enzymes AmbC and AmbD, and the noncanonical domains of 
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AmbE. Elucidating the full biosynthetic pathway of AMB will give a better understanding of 
how oxyvinylglycines are made by NRPS enzymes and provide additional insights into the 
mechanisms of non-canonical NRPS enzymes.  
Materials and Methods 
Synthesis of protected amino pantetheine intermediate (1) 
 
(4R)-N-(3-((2-aminoethyl)amino)-3-oxopropyl)-2-(4-methoxyphenyl)-5,5-dimethyl-1,3- 
dioxane-4-carboxamide. 3a was synthesized following the procedure of Beld et al.79 
 
N-(tert-butoxycarbonyl)-S-(2-nitrobenzyl)-L-cysteine. S-(2-nitrobenzyl)-L-cysteine was 
prepared according to previous literature (ref). L-cysteine (0.625 g, 5.15 mmol) was 
dissolved in H2O (10 mL). N,N-diisopropylethylamine (DIPEA, 0.831 mL) was added to the 
solution dropwise on ice. To this reaction, a solution of 2-nitrobenzyl bromide (1.014 g, 4.7 
mmol) in methanol (10 mL) was added dropwise on ice. The reaction was allowed to stir for 
30 min before it was allowed to warm to room temperature. After 1 hour at room 
temperature, the precipitate was filtered, washed with ethyl acetate (2 x 10 mL), and 
44 
collected. The collected precipitate was then dried under reduced pressure to give a pale-
yellow powder (0.773 g). This crude product was added to 5 mL of H2O, and sodium 
bicarbonate (0.512 g, 6.1 mmol) was added to the solution. Boc anhydride (Boc2O, 0.557 
mL, 2.4 mmol) dissolved in THF (2 mL) was added dropwise on ice. After 30 min the 
reaction was allowed to warm to room temperature and stirred overnight. The reaction was 
then dried under reduced pressure and resuspended in ethyl acetate. The pH was adjusted to 
~3.0, and then the solution was washed with brine. The organic layer was dried with sodium 
sulfate and then dried under reduced pressure to give a yellow oil (0.77 g, 46.0% yield over 2 
steps). 1H NMR (400 MHz, Chloroform-d) δ 9.74 (s, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.57 (td, 
J = 7.6, 1.4 Hz, 1H), 7.51 – 7.40 (m, 2H), 5.37 (d, J = 7.3 Hz, 1H), 4.59 – 4.53 (m, 1H), 4.20 
– 4.06 (m, 3H), 3.00 (dd, J = 14.0, 4.9 Hz, 1H), 2.90 (dd, J = 14.0, 5.6 Hz, 1H), 2.07 (s, 1H), 
1.48 (s, 0H), 1.47 (s, 9H), 1.32 – 1.23 (m, 1H). 
 
Methyl S-(2-nitrobenzyl)-L-cysteinate. L-cysteine hydrochloride (0.884 g, 5.15 mmol) was 
dissolved in H2O (10 mL). DIPEA (1.662 mL) was added to the solution dropwise on ice. To 
this reaction, a solution of 2-nitrobenzyl bromide (1.014 g, 4.7 mmol) in methanol (10 mL) 
was added dropwise on ice. The reaction was allowed to stir for 1 h before it was allowed to 
warm to room temperature. The reaction stirred for 30 min at room temperature before the 
product was extracted with ethyl acetate (3 x 20 mL). The organic layer was dried over 
sodium sulfate then dried under reduced pressure to give a yellow oil (1.635 g). 1H NMR 
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(400 MHz, Chloroform-d) δ 7.92 (dt, J = 8.1, 1.7 Hz, 1H), 7.59 – 7.46 (m, 2H), 7.38 (ddd, J = 
8.6, 6.8, 2.1 Hz, 1H), 4.11 (s, 2H), 4.17 – 3.99 (m, 2H), 3.82 (dd, J = 7.2, 4.7 Hz, 1H), 3.68 
(d, J = 3.0 Hz, 3H), 2.92 (dd, J = 13.8, 4.8 Hz, 1H), 2.85 – 2.74 (m, 1H), 1.20 (td, J = 7.1, 6.4, 
3.3 Hz, 1H). 
 
Methyl N-(N-(tert-butoxycarbonyl)-S-(2-nitrobenzyl)-L-cysteinyl)-S-(2-nitrobenzyl)-L-
cysteinate. Compound 1a (0.536 g, 1.5 mmol) was dissolved in DCM (11.2 mL). The 
solution was placed on ice, and DIPEA (0.4 mL, 2.25 mmol) and PyBOP (0.859 g, 1.65 
mmol) were added. The reaction was allowed to stir for 2 min before a solution of compound 
1b (0.446 g, 1.65 mmol) dissolved in DCM (4.8 mL) was added dropwise. After 30 min the 
reaction was warmed to room temperature and allowed to stir for 1.5 h longer. The reaction 
was dried under reduced pressure and then purified by normal phase flash chromatography 
using Hexane/EA solvent system to afford compound 2a (0.546 g, 59.8% yield) as a yellow 
oil. 1H NMR (400 MHz, Chloroform-d) δ 8.06 – 7.97 (m, 2H), 7.63 – 7.53 (m, 3H), 7.51 – 
7.40 (m, 3H), 7.16 (d, J = 7.9 Hz, 1H), 5.41 (s, 1H), 4.77 (dt, J = 7.7, 5.3 Hz, 1H), 4.34 (s, 
1H), 4.22 (d, J = 13.6 Hz, 1H), 4.19 – 4.01 (m, 3H), 3.77 (d, J = 5.6 Hz, 3H), 3.04 – 2.86 (m, 




Compound 2a (500 mg, 0.821 mmol) was dissolved in THF (7.4 mL) and methanol (6.57 
mL). The reaction was cooled on ice, and then 0.4 M NaOH in H2O (6.43 mL) was added 
dropwise. The reaction was taken off ice and allowed to stir for 1 hour. The reaction was then 
acidified using HCl to pH 3.0, and product was extracted using EA (3 x 10 mL). The organic 
layer was washed with H2O (15 mL) and then brine (15 mL). The organic layer was then 
dried over sodium sulfate and dried under reduced pressure to afford compound 2b (0.438 g, 
90% yield) as a yellow solid.  
1H NMR (400 MHz, Chloroform-d) δ 8.04 – 7.96 (m, 3H), 7.62 – 7.53 (m, 5H), 7.50 – 7.38 
(m, 6H), 5.47 (s, 1H), 4.82 – 4.74 (m, 1H), 4.47 (s, 1H), 4.22 – 4.04 (m, 6H), 3.06 (dd, J = 
14.0, 5.0 Hz, 1H), 2.96 (d, J = 11.4 Hz, 1H), 2.84 (s, 4H), 2.07 (s, 1H), 1.46 (s, 9H), 1.41 (s, 






tetraazaheptadecan-14-yl)carbamate. Compound 2b (154 mg, 0.26 mmol) was dissolved 
in DCM (8 mL). On ice, HATU (108.6 mg, 0.29 mmol) and DIPEA (68 µL, 0.39 mmol) 
were added to the reaction. The reaction was allowed to stir for 10 min before the dropwise 
addition of compound 3a (108.6 mg, 0.29 mmol). After 15 min the reaction was warmed to 
room temperature and stirred overnight. The reaction was dried under reduced pressure and 
purified by prep HPLC using a Phenomenex Luna C18 column using H2O with 0.1% TFA as 
solvent A and ACN with 0.1% TFA as solvent B to afford compound 4a (167.4mg 67.3% 
yield). 1H NMR (400 MHz, Chloroform-d) δ 8.02 (td, J = 8.2, 7.8, 4.4 Hz, 2H), 7.91 – 7.82 
(m, 1H), 7.71 (s, 0H), 7.65 – 7.40 (m, 8H), 7.23 (s, 1H), 7.19 – 7.06 (m, 1H), 7.06 – 7.00 (m, 
1H), 6.92 (dd, J = 8.7, 1.9 Hz, 2H), 6.68 (s, 1H), 5.48 (s, 1H), 4.54 – 4.42 (m, 1H), 4.25 – 
3.96 (m, 8H), 3.92 (s, 1H), 3.82 (s, 2H), 3.79 – 3.61 (m, 2H), 3.59 – 3.47 (m, 2H), 3.38 (s, 
4H), 3.22 (pd, J = 7.7, 4.7 Hz, 4H), 2.87 (dddd, J = 29.5, 22.8, 13.8, 6.8 Hz, 2H), 2.47 (dt, J = 
12.7, 5.9 Hz, 2H), 2.06 (s, 3H), 1.55 – 1.37 (m, 20H), 1.28 (t, J = 7.2 Hz, 4H), 1.15 – 0.99 




2-thia-6,9,12-triazapentadecan-15-yl)-2,4-dihydroxy-3,3-dimethylbutanamide. On ice, 
compound 4a (48 mg, 0.050 mmol) was dissolved in 4 mL of 1:1 DCM:TFA and 300 µL of 
water. After 1 h the reaction was dried under reduced pressure, and the resulting oil was 
dissolved in 85% acetic acid:water and stirred overnight. The reaction was dried under 
reduced pressure and purified by prep HPLC using a Phenomenex Luna C18 column using 
H2O with 0.1% TFA as solvent A and ACN with 0.1% TFA as solvent B to afford 
compound 1 (1.8 mg, 4.9% yield). Deprotection was confirmed by LC-HRMS. 
Photodeprotection of cysteine intermediate 
A solution of 250 µM compound 1, 1 mM Ascorbic Acid, 2.5 mM semicarbazide in 
potassium phosphate buffer pH 6.0 in borosilicate glass was illuminated by UV A. The extent 
of deprotection was measured by LC/MS, and >90% deprotection was observed in 3 hours. 
In vitro HlmE T domain loading of CoA analogue  
The photodeprotected product in the photodeprotection solution was adjusted to pH 
7.5 using 0.1 M NaOH. To 400 µL of photodeprotection solution 9 mM ATP, 10 mM MgCl2, 
0.5 µM CoAA, 0.7 µM CoAD, and 1.5 µM CoaE were added to a final volume of 500 µL. 
The assay was then incubated at 37 ºC overnight to form the CoA intermediate. To the 
complete CoA-analogue-forming assay, 100 µM HlmE T domain and 1 µM of Sfp were 
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added and allowed to mix at 37 C for 1 h. LC-MS was used to determine the extent of 
substrate loading onto the T domain. 
HlmB and HlmD in vitro activity assays 
To 50 µL of T domain loaded substrate, 1 mM of Tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP) and 1 mM of ascorbic acid were added to the reaction and allowed to 
mix for 10 min at r.t. Then 20 µM of HlmB or HlmD or both were added and mixed for 1 h 
at r.t. Finally, 12.5 mM of iodoacetamide was added and allowed to mix at r.t. for 10 min 
before T domain analysis by LC/MS. Additional cofactors such as NADH, NAD+ were 
added at 1 mM concentration with TCEP when included. 
Protein Expression and Purification 
For protein purification, E. coli BAP-1 were transformed with pLIC-His-ambB. E. 
coli BL-21(DE3) were transformed with pLIC-His-ambC and pLIC-His-ambE individually. 
E. coli BL21-CodonPlus(DE3) RIPL cells were transformed with pLIC-His-ambD. All 
transformations were performed by electroporation.  E. coli were routinely cultured at 37 ºC.  
 AmbB was expressed in 1L cultures of LB Miller media containing 100 µg/mL 
ampicillin. The cultures were grown at 37 °C with shaking to an OD600 of 0.6, which were 
then induced by the addition of 0.5 mM IPTG, and grown for another 18 hours at 16 °C. The 
cells were then pelleted by centrifugation at 3000 x g for 30 min. The cells were resuspended 
for lysis in Buffer A (50 mM HEPES pH 7.5, 200 mM NaCl, 5 mM β-mercaptoethanol 
(BME), and 30 mM imidazole) and sonicated using a Fisher Scientific Sonic dismembrator 
model 500 (1.5 min total on time of cycles of 30% amplitude with 0.5 sec pulse on, and 1.5 
sec pulse off). The lysed cells were centrifuged at 34,500 x g for 30 min at 4 °C. The 
supernatant was filtered through a 0.45 µm filter before purification by FP-LC. The filtered 
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supernatant was purified by Ni affinity chromatography using a GE HisTrap HP Ni column. 
Buffer A was used as wash buffer, and Buffer B (50 mM HEPES pH 7.5, 200 mM NaCl, 5 
mM BME, and 300 mM imidazole) was used as elution buffer. Fractions containing AmbB 
were combined and concentrated to a final volume of 3.5 mL using a Millipore centrifugal 
filter with a 30 kDa molecular weight cut off. The combined fractions were then applied to a 
GE HiLoad 16/600 Superdex 200 pg column that had been equilibrated with Buffer C (50 
mM HEPES pH 7.5, 200 mM NaCl, 5 mM BME, and 10% glycerol). Fractions containing 
pure AmbB were pooled and again concentrated using a Millipore centrifugal filter with a 30 
kDa molecular weight cut off to a final concentration of 50–200 µM. AmbB was then flash 
frozen in liquid nitrogen and stored at −80 °C until needed.  
AmbE, AmbE S1958A (TE mutant), AmbE S1819A (T2 mutant), and AmbE T 
domains were expressed and purified following the method above. AmbC and AmbD were 
expressed and purified by Ni affinity chromatography as described above, and then AmbC 
and AmbD were desalted using a GE PD-10 column equilibrated in Buffer C. AmbC and 
AmbD were then concentrated using a Millipore centrifugal filter with a 10 kDa molecular 
weight cut off, and frozen and stored similar to AmbB. AmbE T domains, AmbES1958A 
(TE mutant), and AmbE S1819A (T2 mutant) plasmids were expressed in BL21. 
Reconstitution of AMB enzymes in vitro  
Enzyme activity was reconstituted in vitro by incubating 1.25 µM AmbB and 2.5 µM 
AmbE in 25 mM potassium phosphate buffer pH 7.5 with 0.5 µM Sfp, 1 mM CoASH, and 4 
mM MgCl2 at 28 °C for one hour. To this solution 1 mM alanine, 1 mM glutamic acid, 1 mM 
α-KG, 1 mM sodium ascorbate, 320 µM S-adenosylmethionine, 2 mM ATP, and 200 µM 
ammonium iron(II) sulfate were added. The reaction was initiated by the addition of 7.2 µM 
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AmbD and 13.7 µM AmbC, which brought the final volume to 100 µL. The assay was 
incubated at 28 °C for 2 hours. To quench the reaction, 100 µL of acetonitrile was added and 
the assay was cooled to −20 °C for 20 min. The assays were then centrifuged at 14,000 x g 
for 5 min, and then the supernatant was taken for analysis by LC/MS. 
AmbE T domain 1 glutamate-loading assays and AmbC and AmbD activity 
To load the phosphopantetheine (Ppant) arm onto T domains in trans, 2 µM Sfp was 
added to a solution containing 25 mM potassium phosphate buffer pH 7.5, 2 mM MgCl2, 1 
mM CoA, and 150 µM AmbE T domain 1 (T1). The assay was shaken at 28 °C for 1 hour. 
The greatest amount of amino acid loading was observed when 10 µL of Ppant loading assay 
was added to 25 mM potassium phosphate buffer pH 7.5, 2 mM ATP, 1 mM amino acid, and 
2 µM AmbE, or AmbE S1958A to a final volume of 50 µL. The assay was incubated at 28 
°C for 2 hours. AmbE was used to load glutamate onto T1.  
To test tailoring enzyme activity, 50 µM AmbC and AmbD were separately incubated 
with 1 mM ammonium iron(II) sulfate and 1 mM ascorbic acid in 25 mM potassium 
phosphate buffer pH 7.5 for 10 min prior to activity assays. For each assay, 5 µL of iron 
incubated AmbC or AmbD and 1 mM α-KG were added to 50 µL of T1 loading assay 
described previously. The assay was allowed to incubate at 28 °C for 2 hours. Samples were 
spun down at 20,000 x g and the supernatant was taken for analysis by LC/MS. 
Chemical capture of NRPS-bound intermediates using cysteamine 
The one-pot in vitro AMB reconstitution reaction was conducted using either 
AmbES1819A or AmbE-S1958A in place of wild-type AmbE to accumulate biosynthetic 
intermediates bound to AmbE. A sample of freshly prepared 50 mM cysteamine 
hydrochloride was added to the one-pot assay as the final component immediately after 
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adding all other substrates and cofactors. Individual enzymes (AmbB, AmbC, or AmbD) or 
substrates (Ala or SAM) were excluded from the reaction mixture in separate reactions. 
Isotopically labeled glutamic acids were used in place of L-glutamic acid for corresponding 
reactions. The modified assays containing cysteamine were incubated at room temperature 
for 2 hours and quenched and spun down as described previously. Supernatants were Fmoc 
derivatized by adding 25 µL of samples to 90 µL of ACN and 50 µL of 200 mM sodium 
borate buffer pH 9.0. To this solution, 90 µL of 18 mM Fmoc-Cl dissolved in acetonitrile 
was added and samples were incubated at room temperature for 10 min before analysis by 
LC-MS. 
Analysis by LC/MS 
Supernatants from small molecule in vitro samples were analyzed using an Agilent 
Technologies 6520 Accurate-Mass Q-TOF LC-MS. Data were collected using positive ion 
mode ESI mass spectrometry with the following parameters: gas temperature 300 °C, 
fragmentor 175 V, and skimmer 65 V.  Underivatized samples were separated using a 150 
mm Phenomenex Kinetex C18 column with 2.6 µm particle size and 100 Å pore size. 
Solvent A consisted of 0.1% formic acid in water (Fisher), and solvent B consisted of 0.1% 
formic acid in acetonitrile (Fisher). Fmoc derivatized samples were separated using a 50 mm 
Phenomenex Gemini C18 column with 5 µm particle size and 110 Å pore size. Solvents A 
and B were same as above. 
Supernatants from T domain studies were analyzed using an Agilent Technologies 
6520 Accurate-Mass Q-TOF LC-MS/MS. Data were collected using positive ion mode ESI 
mass spectrometry with the following parameters: gas temperature 350 °C, fragmentor 250 
V, skimmer 65 V. Masses chosen for MS2 were selected automatically based on abundance 
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and charge state over 3, and masses were fragmented with a collision energy of 35 V. The 
protein samples were separated using a 150 mm Restek Viva C4 column with 5 µm particle 
size. Solvents used for separation are the same as above. The MS data were used for protein 
deconvolution and whole protein analysis. The MS2 data were used for Ppant ejection 
analysis.82 
Results 
HlmE T domain was loaded with the synthetic compound 1 
Compound 1 was synthesized and photodeprotected using UV light in the presence of 
ascorbic acid and semicarbazide and then converted to the respective CoA analogue using 
CoaA, CoaD, CoaE and Sfp, (Figure 3.4). However, the photodeprotection required acidic 
conditions, but the enzymes of the CoA forming assay required pH 7.5. Thus, to complete the 
entire deprotection and loading of substrate onto the HlmE T domain 1, we first 
photodeprotected at pH 6.0, then without purification, the pH was adjusted to 7.5 for the CoA 
forming and T domain loading assays.  
 
Figure 3.4 – Scheme for in vitro loading of HlmE T domain with synthetic cysteine dipeptide 
intermediate. Compound 1 was photodeprotected and then loaded onto HlmE T domain. 
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HlmB and HlmD were not active using T domain loaded substrate 
Figure 3.5 shows that compound 1 was successfully loaded onto HlmE T domain 
after photodeprotection, but neither HlmB nor HlmD showed any activity with this substrate. 
A variety of cofactors known to be associated with flavoproteins were added to the assays, 
such as NADH, NAD+, and ascorbic acid, but no modification of substrate was detected by 
LC/MS. Additionally, to determine whether the lack of detection was due to insufficient 
changes in mass, iodoacetamide (IAA) was used to derivatize free thiols in order to increase 
the mass shift that would occur if the thiols were modified. Again, no difference was 
observed in whole protein MS or MS2 Ppant ejection between the samples with or without 
tailoring enzymes (Figure 3.5). Attempts to use cysteamine cleavage to identify intermediates 
were also unsuccessful, and activated cysteine was never observed by LC-MS. It is likely that 
the thiols of cysteine prevent the expected dimerization of cysteamine and complicated the 
analysis by LC-MS. 
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Figure 3.5 – HlmB and HlmD do not show activity when incubated with the synthetic 
cysteine dipeptide substrate linked to the T domain of HlmE. TCEP reduced disulfide bond, 
and iodoacetamide was used to derivatize free thiols for greater mass shifts. A) Analysis of in 
vitro reactions by whole protein mass spec. B) Analysis of in vitro reactions by MS2 Ppant 
ejection. 
Reconstitution of AMB biosynthetic enzymes produced Ala-AMB in vitro 
We cloned and purified all four biosynthetic enzymes from the amb gene cluster and 
reconstituted activity in a one-pot assay by incubating these enzymes with their predicted 
substrates and cofactors in a single reaction. Surprisingly, LC-MS analysis of the assay 
detected a product with a mass that corresponds to an ala-AMB dipeptide (2) rather than an 
Ala-AMB-Ala tripeptide observed previously (Figure 3.6).72 Ala-AMB was not produced 
when enzymes were denatured before the assay, or when the cofactor α-ketoglutarate (α-KG) 
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was absent from the reaction. To confirm its structure, the Ala-AMB product was Fmoc 
derivatized and then purified for analysis by NMR.  
 
Figure 3.6 – Ala-AMB was the product of in vitro reactions using the four biosynthetic Amb 
enzymes. Extracted ion chromatograms from the one-pot assay and negative controls. α-
ketoglutarate (α-KG) is a necessary cofactor of AmbC and AmbD. 
Truncated AmbE T1 domain assays elucidate AmbC activity 
Next, we characterized the chemical reactions that convert glutamate to AMB. In 
order to elucidate the modifications that occur while glutamate is tethered to AmbE, we 
loaded glutamate onto the first T domain of AmbE (T1) to act as a substrate for the tailoring 
enzymes. We performed glutamate loading onto the T1 by using Sfp to add the Ppant arm to 
T1, and then full length AmbE to activate glutamate and load it onto the Ppant arm of T1 
(Figure 3.7A). Incubating T1 with AmbC led to a 16 Da increase in mass, suggesting AmbC 
hydroxylates glutamate and that AmbC is the first enzyme to modify glutamate in the 
pathway. However, we did not observe AmbD activity on glutamate or the hydroxylated 
glutamate substrate bound to T1 during sequential assays (Figure 3.7B). Next, we used the 
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tandem MS technique known as Ppant ejection,82 to confirm that the hydroxylation had 
occurred on glutamate, and not another residue of T1. In addition, we used differentially 
deuterated glutamates as substrates to demonstrate that AmbC selectively hydroxylated the 




Figure 3.7 – AmbC hydroxylated glutamate loaded on AmbE T1, but AmbD showed no 
activity. A) The scheme of loading glutamate onto AmbE T1 for whole protein analysis by 
LC-MS, and the structure of Ppant fragment detected in MS2. B) Deconvoluted protein mass 
spectra of glutamate modification on AmbE T1. AmbC hydroxylates glutamate, but AmbD 
did not show any activity. C) Mass spectra of Ppant ejection assays using deuterated 
glutamate substrates to determine AmbC regioselectivity. Substrates were: L-Glu (top), 
2,4,4-D3-L-Glu (middle), and 3,3-D2-L-Glu (bottom). 
Cysteamine cleavage identifies multiple intermediates of AMB biosynthesis  
Next, we used cysteamine as a chemical probe to identify additional intermediates of 
the pathway. Cysteamine assays were performed by adding cysteamine to the one-pot assays 
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that included the TE mutant of AmbE. Since the TE domain cleaves products and 
intermediates from AmbE, we used the TE mutant to buildup intermediates on AmbE that 
could then only be cleaved by cysteamine. Additionally, the assays were Fmoc derivatized 
before analysis by LC-MS to increase the retention time of intermediates on reverse-phase 
columns and to achieve better signal intensity by MS (Figure 3.8A). Figure 3.8B shows 5 
different intermediates identified by cysteamine capture across 5 assay conditions, a 
significant improvement over the T domain approach, which only proceeded through the first 
hydroxylation of AmbC. We were able to detect the final product, Ala-AMB, in the full 
assay, which confirms that the enzymes are still active in the presence of cysteamine. When 
AmbC was excluded, unmodified glutamate (4) was detected on the assembly line, 
suggesting that AmbC is responsible for the first modification, which confirmed the T 
domain result. Exclusion of AmbD led to the detection of monohydroxy-glutamate (5), 
suggesting that AmbD catalyzes the second modification after AmbC hydroxylation. 
Omission of S-adenosyl methionine (SAM), which is required for the methyltransferase 
domain, led to detection of dihydroxy-glutamate (6), suggesting that O-methylation occurs 
after both hydroxylations. Lastly, omission of AmbB resulted in accumulation of a 
dihydroxylated and methylated glutamate (7), but not AMB, suggesting that condensation 
with alanine occurs after the hydroxylations and O-methylation, but prior to the dehydration 




Figure 3.8 – Capture and detection of AMB biosynthetic intermediates using cysteamine 
cleavage, which revealed the order of biosynthetic steps. A) Scheme of cysteamine cleavage 
of covalently linked intermediates in NRPS pathways, followed by Fmoc derivatization. B) 
Mass spectra captured intermediates during reconstitution of AMB biosynthesis using the TE 
mutant AmbE S1958A. While the proton adduct of derivatized 4 is detected, it has been 
excluded for clarity.   
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 To determine the regioselectivity of each modification, we used 2,4,4-D3-glutamate 
as a substrate for the cysteamine cleavage assay (Figure 3.9). We observed that AmbC 
hydroxylation did not remove a deuterium, which confirmed the T domain assay result 
(Figure 3.7) demonstrating that AmbC hydroxylates glutamate at the C3 position. AmbD did 
remove a deuterium, and it is assumed from the final structure of AMB that this must have 
occurred on C4 of hydroxy-glutamate. Interestingly, one of the deuteriums of 7 was lost 
during the conversion to ala-AMB, and initially it was unclear whether this was the C2 or the 
remaining C4 deuterium (Figure 3.9). 
 
Figure 3.9 – The cysteamine cleavage assay was repeated using 2,4,4-D3-L-Glu as a 
substrate to confirm regioselectivity of modifications. Assay conditions and analysis were the 
same as Figure 3.8. 
 We were able to determine which deuterium remained by feeding differentially 
deuterated glutamates as substrates for the one-pot reaction. When 3,3-D2-glutamate, 4,4-D2-
glutamate and 2,4,4-D3-glutamate were used as substrates, the ala-AMB product contained 
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only one deuterium (Figure 3.10). Since one of the deuteriums of 4,4-D2-glutamate remained 
in the substrate, we can infer that the deuterium remaining from the 2,4,4-D3-glutamate 
substrate was at the C4 position, which meant that during the conversion of compound 7 to 3, 
the C2 deuterium was lost. We hypothesized that this was due to a 2,3-dehydro intermediate 
resulting from the dehydration of the hydroxyl at C3.  
 
Figure 3.10 – AMB products of differentially deuterated glutamate substrates show loss of C2 
deuterium.  
 After elucidating multiple steps of the biosynthesis of AMB, we sought to identify 
where on AmbE these modifications were taking place. For this experiment we used the 
mutant AmbE S1819A, which lacks the serine necessary for Ppant modification at T2, 
leaving T1 as the only domain where the substrate can be tethered (Figure 3.11A). The full 
one-pot cysteamine cleavage assays using AmbE S1819A did not produce ala-AMB, and 
instead a small amount of alanyl-3-hydroxy-4-methoxy-Glu (8) was produced. This result 
suggests that both hydroxylations, the methylation, and the alanine condensation all occurred 




Figure 3.11 – The cysteamine cleavage assays were repeated using AmbE S1819A (T2 
mutant) in place of AmbE S1958A (TE mutant). A new intermediate was detected, 
derivatized 8, which was only present in the full assays. A) Scheme showing halting of 
biosynthesis due to mutation in T2 domain. B) Mass spectra of captured intermediates using 
AmbE S1819A in cysteamine cleavage assays. C) Expansion of derivatized 8.  
Discussion 
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The fact that intermediates of NRPS pathways are covalently bound to assembly-line-
like enzymes has made elucidating the roles of tailoring enzymes and noncanonical NRPS 
domains inherently difficult. Here three different methods of studying NRPS pathways were 
tested and each had varying degrees of success. To study holomycin biosynthesis, we utilized 
a chemoenzymatic approach that has previously been used to load fluorescent tags and 
markers to T domains.78,79 Using this chemoenzymatic approach, a cysteine dipeptide 
intermediate was successfully loaded onto the HlmE T domain (Figure 3.4), but neither 
HlmB nor HlmD showed any activity with this substrate in vitro (Figure 3.5). This result 
highlighted one of the key drawbacks of this chemoenzymatic approach: the intensive effort 
necessary to test a single substrate compared to typical in vitro reaction assays. Each 
substrate must be individually synthesized, making it difficult to rapidly test many possible 
substrates. Also, without a positive control, it is unclear which part of the assay was 
responsible for the lack of activity. It may be possible that the enzymes were inactive, 
necessary cofactors were missing, or the substrate was incorrect. Additionally, the native 
substrate of tailoring enzymes are linked to the full NRPS, not just the T domain, and it is has 
previously been shown that protein-protein interactions with additional domains of an NRPS 
are necessary for some tailoring enzymes.74,75 While HlmB and HlmD are interesting targets 
to study since they may catalyze novel sulfur chemistry in biological systems, the 
chemoenzymatic approach was not suitable for identifying possible substrates without further 
information about the pathway. One way to ensure that the substrates of tailoring enzymes 
are correct would be to use the NRPS from the pathway to load an amino acid onto the T 
domain. Unfortunately, it has been shown that the thiols of cysteine will cleave the thioester 
bond of the Ppant arm releasing the cysteine dipeptide, making the holomycin pathway 
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difficult to study using this technique as well.68 Additionally, attempts to use cysteamine to 
cleave intermediates were also unsuccessful (data not shown). It is possible that the thiols of 
cysteine may form mixed disulfides with cysteamine forming multiple different compounds 
for any intermediate cleaved from the NPRS, which would complicate the analysis by LC-
MS. However, we were able to demonstrate that the AMB pathway is amenable to both of 
these methods. 
 The activity of AmbC was identified using truncated AmbE T1 loaded with glutamate 
as a substrate.  To our knowledge, this was the first example of using the full length NRPS to 
load the native substrate onto a truncated T domain to be used as a substrate for tailoring 
enzymes (Figure 3.7). While this method was used to successfully identify the activity and 
regioselectivity of AmbC, no activity was observed for AmbD. From additional cysteamine 
cleavage assays, we have shown that the substrate of AmbD was in fact hydroxylated 
glutamate, which indicates that other interactions between AmbD and AmbE might be 
necessary for hydroxylation by AmbD. Similar to the chemoenzymatic approach, a 
significant limitation of using these truncated T domain studies is that the T domain alone is 
not the native substrate of the tailoring enzymes, and it appears as though the entire NRPS 
may often be necessary. One method that uses complete NPRS enzymes and does not suffer 
from this problem is the in vitro cysteamine cleavage assay. 
 The only example of cysteamine being used as a thioester probe in the literature is 
with a PKS from the calicheamicin pathway.48 Belecki and Townsend used cysteamine to 
cleave intermediates that covalently bound to the PKS CalE8 during purification, which lead 
to extremely low concentrations of intermediates. We improved this technique by including 
cysteamine during AMB production in in vitro assays; thus, every time cysteamine cleaved 
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off an intermediate, the pathway continued to activate and modify additional substrates 
resulting in greater concentrations of cleaved intermediates. Additionally, the free amine 
present in cysteamine after cleavage and dimerization allowed for Fmoc derivatization for 
better sensitivity regardless of the intermediate being cleaved (Figure 3.8A). Using 
cysteamine as a chemical probe, multiple intermediates were cleaved from AmbE and 
detected by LC-MS. By altering the enzymes, cofactors, and substrates present in the assays, 
various intermediates were detected, and each chemical modification could be assigned to a 
specific enzyme (Figure 3.8B). AmbC and AmbD hydroxylated glutamate at carbons C3 and 
C4, respectively. The methyltransferase domain then methylated the hydroxyl on C4, 
followed by the condensation of alanine onto the modified glutamate (7) by the AmbB 
(Figure 3.12). Additionally, using the AmbE T2 mutant in the cysteamine cleavage assays 
demonstrated that all of these reactions occurred on the T1 domain of AmbE (Figure 3.11). 
The regioselectivity of AmbC and AmbD were also determined by using the 2,4,4-D3-
glutamate substrates in the cysteamine cleavage assay (Figure 3.9). The only reaction that 
remains uncharacterized is the dehydration and decarboxylation of compound 8 that 
ultimately produces the final ala-AMB product (Figure 3.12). Phylogenetic analysis of the 
AmbE C* domain identifies homology to other C domains that are predicted to catalyze 
dehydrations of serine and threonine to produce dehydroalanine or dehydrobutyrine.83,84 Thus 
it is possible that the C* domain may catalyze the dehydration of C3 to make the 2,3-dehydro 
intermediate 9 before decarboxylation. However, additional activity studies are necessary to 
characterize the final two transformations to form AMB. 
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Figure 3.12 – Proposed enzymatic biosynthesis of Ala-AMB 
Conclusion and Future Directions 
 Comparing the three methods described in this study, cysteamine cleavage was shown 
to be the most effective at characterizing an NRPS biosynthetic pathway, including the 
identification of intermediates and their step-by-step modifications. Using cysteamine 
cleavage in vitro followed by Fmoc derivatization led to increased intermediate 
concentrations; thereby allowing the detection of multiple intermediates of the AMB 
pathway and the determination of the order and timing of the biosynthetic steps necessary to 
produce AMB. Using a combination of deuterium labeled substrates, we discovered multiple 
unexpected chemical transformations, including the hydroxylation of C3 by AmbC before 
subsequent dehydration to the 2,3-dehydro intermediate 9. While loading glutamate onto 
AmbE T1 was a useful technique for determining the activity of AmbC, the fact that AmbD 
was not able to hydroxylate its substrate again showed the limitation of this method; in order 
to study tailoring enzymes, the full NRPS is often necessary for activity, not just the T 
domain. While cysteamine cleavage has only been used to study the AMB and calicheamicin 
pathways thus far, it has the potential to serve as a useful chemical probe in both NRPS and 
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PKS pathways. In pathways where tailoring enzymes have previously been shown to be 
active, cysteamine cleavage could be used to detect intermediates and definitively 
characterize the reactions catalyzed by these tailoring enzymes. However, one disadvantage 
of cysteamine cleavage assays is the fact that free thiols from substrates or cofactors may 
inhibit the expected dimerization of cysteamine and thus complicate the LC-MS analysis, 
potentially limiting the types of pathways that cysteamine may be used to study. Overall, 
cysteamine cleavage in vitro has been shown to be a promising technique to study NRPS and 
PKS systems and for characterizing tailoring enzymes with novel activities, which in turn can 
be used as biocatalysts in synthetic schemes or be used to identify additional enzymes that 




CHAPTER 4: METABOLOMICS AND BIOCHEMICAL STUDIES OF 4-
FORMYLAMINOOXYVINYLGLYCINE BIOSYNTHESIS 
Introduction 
 Pseudomonas fluorescens WH6 is a bacterial strain that was identified as a promising 
biocontrol agent to prevent the growth of grassy weeds. Grassy weeds are a problem for both 
recreational and professional lawns, especially weed strains that show resistance to chemical 
herbicides such as annual bluegrass weeds.85 Additional methods to control grassy weed 
growth are needed to combat the growing prevalence of resistance. Through phenotypic 
screens the culture extracts of WH6 were found to inhibit the germination of bluegrass 
weeds.85  The active metabolite was isolated and characterized as 4-
formylaminooxyvinylglycine (FVG), a member of the oxyvinylglycine class of secondary 
metabolites.36,86,87 The gene cluster responsible for the biosynthesis of FVG in WH6 was 
identified using transposon mutagenesis.88 The cluster was named the growth arrest factor 
vinylglycine (gvg) cluster, and consists of 6 putative enzyme encoding genes, 2 small open 
reading frames (ORFs), 3 putative LysE type transporters, and one transcription regulator 
(Figure 4.1). Interestingly, the cluster encodes a protein GvgC, which belongs to a class of 
proteins with an unknown function. While the C-terminus of GvgC shares 20% homology 
with heme-oxygenases, the larger N-terminus portion of the protein does not have homology 
to any characterized proteins. Also, the putative amidino transferase from the cluster, gvgD, 
is not necessary for FVG biosynthesis, and its purpose in the cluster is unknown.89 GvgD 
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Figure 4.1- Gvg gene cluster and structure of FVG produced by Pseudomonas fluorescens 
WH6. Genes colored red are necessary for FVG production, and the putative function of the 
protein encode by each gene is listed. The core of all oxyvinylglycines is shown in 
comparison to FVG. 
In addition to FVG, two other metabolites that contain the aminooxyvinylglycine core 
have been isolated from Streptomyces. Aminooxyvinylglycine (AOVG) and 
guanidinooxyvinylglycine (GOVG) were also identified for their antifungal activity, but no 
information about their biosynthesis is known.90 Interestingly, AOVG and GOVG are 
structurally similar to canaline and canavanine from plant metabolism, which are used for 
nitrogen storage.91,92 AOVG and GOVG differ from canaline and canavanine by only a beta 
desaturation, suggesting that they may act as antimetabolites to modulate plant metabolism 
(Figure 4.2). Additionally, the biosynthesis of most oxyvinylglycines are not well 
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understood, and those that have been elucidated proceed through different chemical 
transformations.81,93,94 Feeding studies using stable isotope labeled amino acids in growth 
cultures that produce oxyvinylglycines have suggested homoserine is an important precursor 
for the aminoethoxyvinylglycine and rhizobitoxine oxyvinylglycine pathways, which may 
serve as a starting point for studying FVG.93,95 In primary metabolism, homoserine is an 
intermediate in the aspartate-threonine pathway. In bacteria, such as Pseudomonads, the 
conversion of aspartic acid to threonine requires 5 enzymatic steps and contains branching 
points to other pathways at the intermediates homoserine and aspartate semialdehyde. It is 
possible that a metabolite in the aspartate-threonine pathway is a direct precursor for FVG 
biosynthesis. In addition to the oxyvinylglycine core, the presence of an N-O bond in FVG 
can give some insight into the biosynthesis. 
 
Figure 4.2 – Comparing the structures of canaline and canavanine, two plant metabolites, to 
AOVG and GOVG. AOVG and GOVG were previously isolated from a Streptomyces strain 
for their antifungal activity. The only difference between the plant metabolites and the 
oxyvinylglycines is the beta desaturation, which is highlighted in red. 
The antibiotic D-cycloserine was isolated from Streptomyces garyphalus, and inhibits 
the D-ala-D-ala ligase necessary for bacterial cell wall biosynthesis.96,97 While D-cycloserine 
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is not an oxyvinylglycine, the D-cycloserine cluster has many similarities to the gvg cluster 
and generates an N-O bond. In D-cycloserine biosynthesis, a heme-dependent enzyme 
(DcsA) hydroxylates the guanidine group of arginine, and then an arginase (DcsB) cleaves 
the modified guanidine group to produce hydroxyurea. The released hydroxyurea then acts as 
a substrate for a pyridoxal-5’-phosphate (PLP)-dependent enzyme (DcsD) that converts 
acetyl-L-serine to O-ureido-L-serine by first eliminating the acetyl group of acetyl-L-serine 
(Figure 4.3).98,99 Similarly, the gvg cluster has multiple genes that encode proteins with 
analogous putative functions; GvgC is predicted to have a heme binding domain, GvgH is 
predicted to be a PLP-dependent enzyme, and GvgA is predicted to be an esterase, which 
have similar mechanisms to arginases. Due to these similarities, we hypothesized that GvgC 
may form an N-O bond, which is released from a larger metabolite by the esterase GvgA. 
Then, GvgH could utilize a modified homoserine substrate and the product of GvgA to 
produce AOVG. While some of the biosynthesis of FVG remains unknown, the extraction 
and in vitro data presented here provides insights into the biosynthesis of FVG by P. 
fluorescens WH6. 
 
Figure 4.3 – Scheme of D-cycloserine biosynthesis.98,99 DcsA is a heme dependent enzyme, 
DcsB is an arginase, and DcsD is a PLP-dependent enzyme. 
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Materials and Methods 
Culture and extraction conditions of P. fluorescens WH6 
Wildtype (WT) and mutant strains of WH6 were grown under the same conditions. 
Bacterial seed cultures of WH6 were started from a single colony and grown in LB medium 
supplemented with 100 µg/mL ampicillin. 50 µL of seed culture was used to inoculate 50 mL 
of modified Pseudomonas minimal salts media (PMS) as described previously.85 PMS media 
consists of 0.2 g potassium chloride and 1.0 g ammonium phosphate monobasic in 50 mM 
sodium phosphate at pH 7.5 in 1 L. The media was autoclaved before the addition of 20 mL 
of sterile 2% magnesium chloride and 20 mL of sterile 10% glucose. After 24 hours of 
growth, supplements were added to the cultures as needed. The final concentrations of 
supplements were: 5 mM homoserine, 5 mM arginine, 2.5 mM folic acid, 5 mM aspartic 
acid. After 72 hours of growth, cells were pelleted at 4000 x g and cell-free supernatants 
were used for extractions. The cell-free supernatants were dried under vacuum and resulting 
dry solids were extracted with 90% ethanol in water as described previously.86 Extractions 
were then dried under vacuum and resuspended in water at 1/20th the volume of the original 
culture. 
Isotope feeding of WH6 cultures 
Isotope feeding experiments were performed as described above, except that the 
desired amino acids were added to the media before cultures were inoculated with WH6. The 
isotope labeled amino acids were used in place of their corresponding non-labeled amino 
acids as needed. Also, all cultures were supplemented with either 5 mM homoserine or 
aspartic acid in addition to 5 mM arginine. To determine the percent incorporation of 
isotopes, the relative abundances of the expected mass shifts were compared to the parent 
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peak. We then subtracted the natural isotope distribution of the parent peak to find a 
corrected percent incorporation. Since the aspartic acid trials had multiple isotope 
incorporations, we subtracted the natural distribution of GOVG with fewer isotopes 
incorporated when calculating the percentage of GOVG with more isotopes incorporated.  
Derivatization of samples for LC-MS analysis 
Extraction samples were derivatized by 9-Fluorenylmethoxycarbonyl chloride (Fmoc-
Cl) or pentafluorophenylhydrazine before analysis by LC-MS. Underivatized samples were 
analyzed by LC-MS without dilution. For Fmoc derivatization, 25 µL of extraction samples 
was added to 50 µL of 200 mM sodium borate buffer pH 9.0. To this solution, 40 µL of 7.5 
mM Fmoc-Cl dissolved in acetonitrile was added and samples were incubated at room 
temperature for 10 min. Undiluted samples were then analyzed by positive mode LC-ESI-
MS. For pentafluorophenylhydrazine derivatization, 2.5 µL of 50 mM Tris pH 7.5 and 0.5 
µL of pentafluorophenylhydrazine were added to 22 µL of extraction samples. Samples were 
then incubated at 42 ºC for 1.5 hours. After derivatization samples were diluted 1:2 before 
analysis by negative mode LC-ESI-MS. 
Protein Expression and Purification 
GvgA, gvgC, gvgF, and gvgH individually cloned into the pLIC-His vector using the 
ligation independent method described previously.100 Escherichia coli BL21 (DE3) cells 
were transformed with pLIC-His containing a single gene of the gvg cluster. Proteins were 
expressed and purified as described in Chapter 2. The lysis/wash buffer used for Gvg protein 
Ni columns contained 50 mM tris pH 7.5, 100 mM NaCl, 10% glycerol, and 15 mM 
imidazole. The elution buffer contained 50 mM tris pH 7.5, 100 mM NaCl, 10% glycerol, 
and 500 mM imidazole. The storage buffer, which was also used for size exclusion 
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chromatography, contained 50 mM tris pH 7.5, 150 mM NaCl, and 10% glycerol. GvgC, 
GvgF, and GvgG were purified by both Ni-affinity and size exclusion chromatography. 
GvgA was purified only by Ni-affinity chromatography, and buffer exchanged into storage 
buffer using a PD-10 desalting column.  
GvgC CO binding assays 
 Purified GvgC was diluted to a final concentration of 10 µM in 200 mM potassium 
phosphate buffer at pH 8.0. An absorbance scan from 380–500 nm was recorded. A sample 
of 50 µL of 0.4 M sodium dithionite was added to the sample. Another absorbance scan was 
recorded. The sample of GvgC was then placed in a chamber containing carbon monoxide 
for 30 min. Then the final absorbance scan was recorded.  
GvgC NADH consumption assays 
 The GvgC activity shown in Figure 4.8C was measured by first preparing a solution 
of 50 mM tris at pH 7.5 containing100 µM FAD, 1 mM NADH, 1 mM NADPH, and 1 mM 
NH4Cl. Addition of 10 µM GvgC initiated the reaction and brought the final volume to 200 
µL. The absorbance from 300-400 nm was recorded every 2 minutes using a Tecan Infinite 
M1000 Pro. Controls were performed lacking FAD and GvgC. Additional controls shown in 
Figure 4.8D were measured as described above, but these samples had either NADH or 
NADPH, or neither cofactor. 
GvgF carbamoyl transferase assays 
 Each reaction contains 5 mM MgCl2, 5 mM ATP, 2 mM DTT, 2.5 mM carbamoyl 
phosphate, and 1 mM of an amino acid substrate. The reaction was initiated by addition of 
GvgF to a final concentration of 10 µM in 50 mM Tris at pH 7.5. The 20 proteinogenic 
amino acids as well as ornithine were tested as substrates. The samples were incubated for 1 
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hour at 28 ºC and quenched by adding an equal volume of acetonitrile and incubating at −20 
°C for 20 minutes. Samples were spun at 20800 x g for 10 minutes to remove protein 
precipitant. The supernatant was derivatized using Fmoc-Cl by adding 25 µL of reaction 
mixture to 140 µL of 53 mM borate buffer at pH 9.0 in 5:9 water:acetonitrile, and then 
adding 25 µL of 18 mM Fmoc-Cl dissolved in acetonitrile. The samples were incubated at 
room temperature for 10 min and then analyzed by LC-MS. The same assays were also 
performed using GvgC and GvgA in place of GvgF. These samples were quenched and 
derivatized and analyzed using the same procedures. 
GvgH in vitro activity assays 
 Each reaction was initiated by the addition of GvgH to a final concentration of 10 
µM. The other components of the reaction were 50 mM tris at pH 7.5, 1 mM O-
succinylhomoserine (O-SH), and 1 mM α-ketoglutarate. The reactions were incubated at 28 
ºC for up to 2 hours before either Fmoc or pentafluorophenylhydrazine derivatization. Fmoc 
derivatization was performed as described in GvgF quenching. Pentafluorophenylhydrazine 
derivatization involves adding 2 µL of 100 mM pentafluorophenylhydrazine to 50 µL of 
unquenched sample and incubating the mixture at 42 ºC for 1 hour. 
Pentafluorophenylhydrazine derivatized samples were analyzed by negative mode LC-ESI-
MS.  
 GvgH activity was also tested using WH6 WT extracts as substrate. Supernatants of 
WT cultures were extracted as described above. 25 µL of the extracts were buffered with a 
final concentration of 50 mM tris pH 7.5 before the addition of 10 µM GvgH to a final 
volume of 50 µL. The extracts were then quenched and derivatized by Fmoc-Cl, as described 
in the GvgF assays, before analysis by LC-MS. 
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Results 
P. fluorescens WH6 cultures produce AOVG and GOVG in addition to FVG   
We confirmed that cultures of P. fluorescens WH6 grown in modified Pseudomonas 
minimal salts media (PMS) produce FVG. After cultures were extracted as previously 
described,87 they were derivatized using Fmoc-Cl to achieve better separation and signal for 
analysis by LC-MS. In addition to FVG, we detected aminooxyvinylglycine (AOVG) and 
guanidinooxyvinylglycine (GOVG) by LC-MS (Figure 4.4), two new products associated 
with the gvg cluster. We also found that supplementing the PMS media with homoserine, 
arginine, and folic acid modulated the production of all three oxyvinylglycines. The addition 
of homoserine and arginine increased the overall production of all three metabolites, while 







Figure 4.4 – P. fluorescens WH6 produced AOVG and GOVG in addition to FVG. 
Additional supplements added to the cultures changed the relative amounts of each 
oxyvinylglycine produced. Homoserine (Hser) and arginine (arg) were added at 5 mM when 
included, and folic acid was added at 2.5 mM when included. Samples were Fmoc 
derivatized before analysis. The traces shown are combined extracted ion chromatograms of 
all three metabolites. 
To determine which enzymes are necessary for FVG biosynthesis, and identify 
possible intermediates in the pathway, we performed extractions on mutant strains of WH6 
provided by our collaborators.89 Each mutant contains a deletion of a single gene of the gvg 
cluster and was growth for metabolite extractions. We confirmed that gvgA, gvgC, gvgF, 
gvgH, and gvgI were necessary to produce FVG (Figure 4.5). While most mutant strains did 
not produce any oxyvinylglycines, the ΔgvgI mutant produced AOVG and GOVG (Figure 
4.5), suggesting that GvgI catalyzes a late stage formylation of AOVG to FVG. We did not 
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detect any new intermediates in the other mutant strains by LC/MS in underivatized, Fmoc 
derivatized, or pentafluorophenylhydrazine derivatized extracts.  
 
Figure 4.5- The P. fluorescens WH6 WT strain produces AOVG and GOVG and is the only 
strain to produce FVG. The ΔgvgI strain produces GOVG, and a very small amount of 
AOVG. None of the other knockouts produced any oxyvinylglycines. Each culture was 
grown with 5 mM homoserine and 5 mM arginine supplements. The extracts were 
derivatized by Fmoc-Cl before LC/MS analysis. 
Homoserine and aspartic acid are related to the precursor of FVG 
We then performed isotope feeding studies to uncover the precursors of the 
oxyvinylglycine core of FVG. When 15N homoserine was added to the cultures, 15N was 
incorporated into 40% of AOVG based on analysis by MS. Similarly, when arginine with 
both amidino nitrogens labeled with 15N was supplemented in cultures, a single 15N was 
incorporated into 34% of AOVG (Figure 4.6, Table 4.1). The marginal incorporation of both 
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homoserine and arginine when such an excess of each was supplemented to cultures suggests 
that homoserine and arginine are related biosynthetically to the precursors, but not the native 
substrates of the pathway. Additionally, we performed MS/MS on the isotope enriched 
AOVG products, which revealed the location of 15N incorporation was dependent on which 
isotope labeled substrate was added (Figure 4.6). The 15N of homoserine was incorporated at 
the backbone nitrogen of AOVG and the 15N of arginine was incorporated at the side chain 
nitrogen. 
 
Figure 4.6 – Feeding of P. fluorescens WH6 cultures with isotope labeled homoserine and 
arginine shows that backbone of FVG metabolites is from homoserine related metabolites, 
and the side chain nitrogen is from arginine guanidine related metabolites. The MS traces 
show mass shifts of AOVG from extractions using isotope enriched homoserine or arginine 
as supplements. The MS2 traces are tandem data of labeled dehydro-canaline, which show 




Labeled amino acid Unlabeled 15N incorporation 
None 99% 1% 
Homoserine  60% 40% 
Arginine 66% 34% 
 
Table 4.1 – Isotope incorporation from homoserine and arginine into AOVG. Percentages are 
the amount of AOVG that is labeled by each isotope. The 1% labeling without the addition of 
labeled amino acids shows the uncertainty of measurements. The values listed are from a 
single trial. 
Isotope labeled aspartic acid was also used to determine the origin of the carbon 
backbone of FVG. We used aspartic acid in place of homoserine because 13C labeled 
homoserine is not commercially available. With aspartic acid being supplemented instead of 
homoserine, the production of GOVG was the greatest among the three metabolites, 
therefore, this product was used for analysis of percentage incorporation. Aspartic acid with 
the backbone 15N was incorporated at a similar percentage to 15N homoserine, suggesting that 
it was also labeling the alpha nitrogen of GOVG, although MS2 experiments were not 
performed to confirm the location. When aspartic acid with all carbons labeled with 13C and 
the nitrogen labeled with 15N was fed into cultures of WH6, we observed a complex isotope 
distribution (Figure 4.7), suggesting that the 15N and carbon backbone are not always 
incorporated together. For GOVG, 24% had just the 15N incorporated, 7% had only the 13C 
backbone incorporated, and 17% had both the 15N and 13C isotopes incorporated (Table 4.2). 
Since the carbon backbone of aspartic acid is never partially incorporated but can be 
separately incorporated compared to the labeled nitrogen, aspartic acid is likely metabolized 
before entering FVG biosynthesis. Thus, the precursor for GOVG is predicted to be a 
metabolite related to aspartic acid.  
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Figure 4.7 - Feeding of P. fluorescens WH6 cultures with 13C and 15N isotope labeled 
aspartic acid shows that the oxyvinylglycine backbone comes from aspartic acid related 
metabolites. With aspartic acid feeding, GOVG had the highest production of the 
oxyvinylglycines, and was used for analysis. Each culture contained 5 mM aspartic acid and 
5 mM arginine and samples were Fmoc derivatized before analysis by LC-MS. 13C location 
are marked by *. 
Label of aspartic acid Unlabeled 15N 13C 15N and 13C 
None 98% 2% 0% 0% 
15N labeled 62% 37% 1% 0% 
13C and 15N labeled 52% 24% 7% 17% 
 
Table 4.2 – Isotope incorporation from aspartic acid into GOVG. Percentages are shown for 
GOVG that is labeled by each isotope. The 2% labeling without the addition of labeled 




In vitro analysis of Gvg enzymes 
 We expressed the Gvg biosynthetic enzymes in E. coli and purified them to 
reconstitute their activities in vitro. Purified GvgC in solution was red with a UV peak at 420 
nm, and analysis by LC-MS identified that GvgC copurified with heme (Figure 4.8A and B). 
A portion of GvgC has homology to the heme oxygenase class of enzymes, which catalyze 
the breakdown of heme into biliverdin. However, GvgC contains an intact heme B, 
suggesting that it performs different chemistry than heme oxygenases in which the heme is 
degraded. We then tested whether GvgC could bind to carbon monoxide similar to p450 
heme proteins. Here, we observed an absorbance shift in the presence of the reducing agent 
dithionite, suggesting that the iron center was reduced from Fe(III) to Fe(II). However, we 
did not detect an absorbance shift after the addition of carbon monoxide, suggesting that 
GvgC has different reactivity than p450 enzymes and globin domains, and may not bind 
oxygen (Figure 4.8B). Next, we tested the activity of GvgC in the presence of the cofactors 
NADH, NADPH, and FAD. In this assay, both NADH and NADPH exhibited maximum 
absorbance at 372 nm, and their oxidized forms did not. GvgC catalyzed the oxidation of 
NADH or NADPH in the presence of a catalytic amount of FAD (Figure 4.8C). Since the 
assays in Figure 4.8C contained both NADH and NADPH, to determine which cofactor was 
being oxidized the assays were repeated with a single cofactor in each sample, which showed 
that GvgC selectively oxidizes NADH in the presence of FAD (Figure 4.8D). However, 
when possible precursors for FVG biosynthesis were included, such as amino acids and 
nitrogen sources, we did not detect any oxidative modifications to the possible substrates. 
Together, this data shows that GvgC is active in vitro, and the heme center is capable of 
oxidative chemistry, but we have not identified the physiological substrate of the enzyme. 
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Figure 4.8 – GvgC does not bind carbon monoxide, but consumes NADH in the presence of 
FAD. A) Mass spectrum of heme b that copurified with GvgC. Calculated m/z = 616.1676 B) 
The iron center of GvgC is reduced by dithionite as seen by a change in absorbance. 
However, the reduced GvgC does not bind carbon monoxide since there is no absorbance 
shift when carbon monoxide is introduced. C) NADH and NADPH have absorbance at 372 
nm. Loss of absorbance in the “+ assay” is due to oxidation of cofactors by GvgC. Both FAD 
and GvgC are necessary for oxidation to occur. D) The loss of absorbance is only in samples 
containing NADH. There is no change in samples with NADPH or samples with neither 
cofactor. 
 GvgH is a homolog of PLP-dependent aminotransferases. Purified GvgH was yellow 
in solution and displayed a UV absorbance spectrum consistent with PLP. When GvgH was 
incubated individually with each of the 20 canonical amino acids or homoserine, no amino 
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transferase activity was observed. However, when O-succinyl-L-homoserine (O-SH) was 
incubated with GvgH, consumption of O-SH was observed, but no new products were 
observed after Fmoc derivatization (Figure 4.9A). Since GvgH is predicted to be an 
aminotransferase, the product is expected to be an alpha-keto acid lacking the primary 
nitrogen necessary for Fmoc derivatization. Instead, we use the derivatizing agent 
pentafluorophenylhydrazine, which has been shown to derivatize alpha-keto acids.47 Using 
the new derivatization method, we detected the cleavage product α-ketobutyric acid (Figure 
4.9A). While the activity is clearly due to GvgH, the rate of the reaction was very slow, 
taking over two hours to reach completion, suggesting that this may not be the native 
substrate of the enzyme. Instead, other naturally occurring homoserine analogues such as O-
acetyl-homoserine or aspartate semialdehyde may be the native substrate. Additionally, we 
found that GvgH could consume AOVG as a substrate from WH6 extracts (Figure 4.9B), 
however, due to the low concentration of AOVG in these extracts, we could not detect a new 
product in the extract mixture. GvgH is likely responsible for the production of AOVG in P. 
fluorescens WH6, and the substrate for this reaction is chemically similar to O-SH, but the 
origin of the N-O bond in AOVG is still unclear. 
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Figure 4.9 – Measuring GvgH activity using O-succinyl homoserine and culture extracts as 
substrates. In all traces, red traces are assays containing GvgH and black traces are controls 
without enzyme. A) i) Scheme of in vitro GvgH reaction and derivatization. ii) Consumption 
of O-succinyl homoserine by GvgH shown by absorbance after derivatization by Fmoc-Cl. 
iii) Conversion of O-succinyl homoserine to the cleaved alpha-keto product derivatized by 
pentafluorophenylhydrazine, show by EIC. iv) Mass spectrum of GvgH reaction. The labeled 
peaks correspond to [M-H]- = 281.0355 and [2M-2H+Na]- = 585.0602. B) Consumption of 
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AOVG from P. fluorescens WH6 extracts in the presence of GvgH. Extracts were derivatized 
by Fmoc-Cl for analysis. 
 We next tested the carbamoyl transferase activity of GvgF in vitro to identify a 
possible substrate for the gvg cluster and a substrate for GvgC or GvgH. Using each of the 20 
proteinogenic amino acids and ornithine as substrates, we observed that GvgF was selective 
for ornithine as a substrate. In the assay, GvgF catalyzed the transfer of the carbamoyl group 
of carbamoyl-phosphate to ornithine to form citrulline (Figure 4.10B). Even the amino acid 
lysine, which has a side chain with one more carbon, showed no activity. However, GvgA 
and GvgC each produced significantly more citrulline than GvgF when incubated with 
ornithine, carbamoyl phosphate, and magnesium chloride (Figure 4.10C). The fact that all 
three enzymes catalyze the production of citrulline suggests that the observed activity is not 
the native function of these enzymes, and instead weak binding of ornithine and cosubstrates 
to the enzymes may be enough to catalyze the formation of citrulline.  Although, the fact that 
all three enzymes interact with ornithine suggests the native substrates of these enzymes may 
be chemically similar to ornithine. Therefore, ornithine is likely not the native substrate of 




Figure 4.10 – GvgF catalyzes the formation of citrulline from ornithine over 1 hour, but the 
rate is slow. A) Scheme of in vitro citrulline formation and derivatization. B) Assays 
containing GvgF (red) produce citrulline, while assays lacking GvgF (black) do not. C) 
Assays containing GvgA (green) and GvgC (blue) produce more citrulline than GvgF (red) 
even though GvgA and GvgC are not predicted to have carbamoyl transferase activity. D) 
Mass spectrum of citrulline formation by GvgC, calculated [M+H] = 387.1710 
 Discussion  
The gvg gene cluster has been shown to be responsible for FVG production, but the 
biosynthesis of FVG had been unknown.89 By performing metabolomic analyses of P. 
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fluorescens WH6 WT and mutant strains we have revealed new insights into the biosynthesis 
of FVG. We identified two new products of the gvg gene cluster, GOVG and AOVG, and the 
structures of these metabolites in comparison to FVG suggest that AOVG is an intermediate 
in the production of FVG and GOVG (Figure 4.4). In each case, the conversion of AOVG 
into either product would require the addition of a single functional group, a formyl group for 
FVG or amidino group for GOVG. These additions are possible due to the gvg cluster 
containing both a putative formyl transferase and amidino transferase, GvgI and GvgD, 
respectively (Figure 4.1). The ability of the ΔgvgI mutant to produce a greater amount of 
GOVG further supports the hypothesis that AOVG is a branching point in biosynthesis of 
FVG and GOVG. Also, the cofactor for formyl transferases is 10-formyltetrahydrofolate, 
which is derived from folic acid. Therefore, when folic acid was added to WH6 cultures, the 
production of FVG increased and the production of GOVG decreased, indicating that there 
are two pathways competing for the same precursor, AOVG. While it is rare, this is not the 
first example in the literature of a single gene cluster producing multiple metabolites.101,102  
While the metabolomics analysis supports the conclusion that the final biosynthetic 
step in the production of FVG involves formylation of AOVG, the biosynthesis of the 
oxyvinylglycine core is still unknown. Previous studies have implicated homoserine as a 
precursor for the oxyvinylglycine AVG,95 however the results of the isotope enriched amino 
acid feeding studies of the gvg were inconclusive. When 15N enriched homoserine was added 
to cultures of WH6, the backbone nitrogen of AOVG was only 40% labeled with 15N, 
indicating that homoserine may only be metabolically close to the precursor of FVG (Table 
4.1). It is possible that homoserine was being metabolized, and then the labeled nitrogen was 
incorporated after separating from the rest of the homoserine carbon backbone. This 
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possibility could not be directly tested due to the fact that 13C labeled homoserine is not 
commercially available, and instead 13C labeled aspartic acid was used as a substitute.  
Aspartic acid is metabolically related to homoserine, and within cells the two 
metabolites can be interconverted enzymatically in two steps. Importantly, the carbon 
backbone of aspartic acid is conserved during the biosynthesis of homoserine. Additionally, 
15N labeled aspartic acid was incorporated into the oxyvinylglycine core of GVG at a similar 
rate to 15N homoserine. When 13C and 15N labeled aspartic acid was supplemented into 
cultures of WH6, the labeled carbons were always incorporated together, but could be 
separately incorporated from the 15N (Figure 4.7, Table 4.2), supporting the hypothesis that 
transformation of aspartic acid needs to occur before modification by the enzymes from the 
FVG pathway. Since both homoserine and aspartic acid appear to be metabolically related to 
the precursor of FVG, and the entire carbon backbone of aspartic acid is incorporated into the 
product, the precursor of FVG is expected to be in the aspartate-threonine pathway. To 
elucidate the biosynthesis and precursor of the AOVG core a series of in vitro studies were 
performed using purified enzymes from the gvg cluster.  
 
Figure 4.11 – Proposed biosynthesis of FVG and GOVG from AOVG by enzymes from the 
gvg cluster.  
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The ΔgvgA, ΔgvgC, ΔgvgF, and ΔgvgH mutants did not produce any AOVG, GOVG, 
or FVG, suggesting that all four encoded enzymes are necessary to produce the 
oxyvinylglycine core. Of these enzymes, GvgC copurified with heme and was found to 
catalyze the oxidation of NADH in the presence of FAD (Figure 4.8). Since heme enzymes 
are capable of forming heteroatom-heteroatoms bonds, including N-O and N-N bonds,99,103 
we propose that GvgC performs redox chemistry in the formation of FVG. However, no 
modification to substrates or formation of heteroatom bonds was observed when GvgC was 
incubated with possible amino acid and nitrogen containing substrates in vitro. GvgF is 
putatively assigned as a carbamoyl transferase and we demonstrated that this enzyme 
exhibited some activity to convert ornithine to citrulline, but the rate of this reaction was very 
slow. Both GvgC and GvgA also performed this reaction in vitro to a greater extent than 
GvgF, suggesting that ornithine is not the native substrate of GvgF (Figure 4.10). GvgF may 
instead utilize a substrate that is chemically similar to ornithine in FVG biosynthesis, but 
additional amino acids and primary amine containing substrates tested with GvgF did not 
show any activity. For GvgH, we confirmed that it is a PLP-dependent enzyme and showed 
that it catalyzed two reactions in vitro. First, GvgH uses AOVG from extracts of WH6 as a 
substrate, but no product was detected due to the low starting concentration of AOVG in the 
complex mixture (Figure 4.9B). PLP-dependent enzymes are reversible catalysts, and this in 
vitro activity suggests the native product of GvgH is AOVG. Second, GvgH catalyzed the 
conversion of O-SH to α-ketobutyric acid, but this reaction was not a productive step in the 
biosynthesis of FVG (Figure 4.9A), thus O-SH may not be the native substrate of GvgH. It is 
possible that GvgH did not show productive catalysis in vitro because a second substrate is 
required to react with the elimination product of O-SH that is still bound to GvgH. We 
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hypothesize the unknown second substrate is the source of the N-O bond found in AOVG. 
However, the addition of common metabolites that contain N-O bonds, such as hydroxyurea, 
nitrate, and nitrite had no effect on the assay, and hydroxylamine actually inhibited the 
activity. Because homologs of the gvgA, gvgC, and gvgF genes often cluster in pathways 
other than the gvg cluster, these genes may encode enzymes that synthesize a different and 
rare N-O bond containing compound. These enzymes likely function to produce a metabolite 
for uses beyond FVG biosynthesis (Figure 4.11). Additional in vitro experiments will be 
necessary to characterize the native functions of enzymes encoded by the gvg cluster and 
determine the structures of intermediates of the pathway. 
Conclusion and Future Directions 
Analysis of extractions of P. fluorescens WH6 revealed that in addition to FVG, the 
gvg cluster produces the oxyvinylglycines AOVG and GOVG, and that AOVG is likely a 
common intermediate in the biosynthesis of FVG and GOVG. However, elucidating the 
biosynthesis of AOVG has been more challenging. Isotope labeling data suggest the 
precursor of AOVG is part of the aspartate-threonine pathway, but in vitro assays were 
unable to confirm this hypothesis. In vitro assays of GvgC were able to identify the cofactors 
of an uncharacterized class of heme-dependent enzymes. Also, GvgH may catalyze the 
formation of the oxyvinylglycine core, but additional studies are needed. The data shown 
here provide a foundation to continue studying FVG biosynthesis, and identify the precursors 
of the gvg pathway, as well as the source of the N-O bond. Once the native functions of these 
enzymes are elucidated, additional clusters that produce uncharacterized oxyvinylglycines or 
N-O bond containing compounds can be identified through bioinformatic searches. 
Additionally, introducing non-native substrates in vitro would allow for the biosynthesis of 
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unnatural oxyvinylglycines with different bioactivates. Also, GvgC represents an 
uncharacterized class of heme-dependent enzymes, and understanding the chemistry it 
performs would allow the class to be utilized for novel biocatalytic reactions in synthetic 
schemes. Overall, there is still much to be discovered from studying the gvg gene cluster that 
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